1 Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days 2 Post-Discharge: A Population-based Cohort Study of Older Adults 3 4 **Running Title:** Medication Clusters and Adverse Drug Events 5 6 Daniala L. Weir PhD¹, Xiaomeng Ma MSc^{2,3}, Lisa McCarthy MSc PharmD^{4,5}, Terence Tang MD^{4,6}, Lauren Lapointe-Shaw MD PhD^{7,8}, Walter P. Wodchis PhD^{2,3}, Olavo Fernandes PharmD⁸, 7 Emily G. McDonald MD MSc^{9,10} 8 9 ¹Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University 10 11 ² Institute of Health Policy, Management and Evaluation, University of Toronto 12 ³ Health System Performance Network, Institute of Health Policy, Management & Evaluation, 13 14 University of Toronto 15 16 ⁴ Institute for Better Health, Trillium Health Partners 17 18 ⁵ Department of Pharmacy, Trillium Health Partners 19 20 ⁶ Department of Internal Medicine, Trillium Health Partners 21 22 ⁷ Department of Medicine, University of Toronto 23 24 ⁸ University Health Network 25 26 ⁹ Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada; 27 ¹⁰ Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, 28 Quebec, Canada 29 Word count: 3900 30 31 **Corresponding Author:** 32 33 Daniala Weir, PhD 34 David De Weid Building 35 Universiteitsweg 99 36 3584 CG Utrecht 37 The Netherlands 38 39 Email: d.l.weir@uu.nl

ABSTRACT

- Background: Certain combinations of medications can be harmful and may lead to serious drugdrug interactions. Identifying potentially problematic medication clusters could help guide prescribing decisions in hospital.
 - **Objectives:** To characterize medication prescribing patterns at hospital discharge and determine which medication clusters are associated with an increased risk of adverse drug events (ADEs) in the 30-days post hospital discharge.
 - **Methods:** All residents of the province of Ontario in Canada aged 66 years or older admitted to hospital between March 2016-February 2017 were included. Identification of medication prescribing clusters at hospital discharge was conducted using latent class analysis. Cluster identification was based on medications dispensed 30-days post-hospitalization. Multivariable logistic regression was used to assess the potential association between membership to a particular medication cluster and ADEs post-discharge, while also evaluating other patient characteristics.
 - **Results:** 188,354 patients were included in the study cohort. Median age (IQR) was 77 (71-84) and patients had a median (IQR) of 9 (6-13) medications dispensed in the year prior to admission. The study population consisted of 6 separate clusters of dispensing patterns post discharge: Cardiovascular (14%), respiratory (26%), complex care needs (12%), cardiovascular and metabolic (15%), infection (10%) and surgical (24%). Overall, 12,680 (7%) patients had an ADE in the 30-days following discharge. After considering other patient characteristics, those in the respiratory cluster had the highest risk of ADEs (aOR: 1.12, 95% CI: 1.08-1.17) compared to all the other clusters, while those in the neurocognitive & complex care needs cluster had the lowest risk (aOR:0.82, 95% CI: 0.77-0.87).

Conclusion: This study suggests that ADEs post hospital discharge are linked to identifiable clusters of medications, in addition to non-modifiable patient characteristics, such as age and certain comorbidities. This information may help clinicians and researchers better understand what patient populations and which types of interventions may benefit patients, to reduce their risk of experiencing an ADE.

KEY POINTS

This study suggests that ADEs post hospital discharge are linked to identifiable clusters of medications, in addition to non-modifiable patient characteristics, such as age and certain comorbidities. This information may help clinicians and researchers better understand what patient populations and which types of interventions may benefit patients, to reduce their risk of experiencing an ADE.

PLAIN LANGUAGE SUMMARY

Certain combinations of medications prescribed to patients when they are being discharged from hospital can increase the risk of adverse events after hospital discharge.

INTRODUCTION

Adverse drug events (ADEs) are common following an acute hospitalization, especially among older adults using multiple medications.1 Post-discharge ADEs arise from multiple factors including inappropriate or low value prescribing, medication changes by the in-hospital care team, side effects related to new medications, and inadequate monitoring of high risk medications (e.g., anti-coagulants, antihyperglycemics, or combinations thereof etc.).²⁻⁴ Medication changes occur often for older adults during hospitalization.⁵⁻⁷ For example, a recent study by our team found that medical and surgical patients discharged from hospital were prescribed an average of 8 medications at discharge with 4 medication changes; 61% of changes were newly prescribed medications, 24% were discontinuations, and 15% were dose changes.8 A related study demonstrated that newly prescribed medications were associated with the highest risk of ADEs following discharge, compared to medications that were continued from prior to admission.3

Associations between specific medications or medication classes and adverse events

Associations between specific medications or medication classes and adverse events following hospitalization have been evaluated (e.g., newly initiated antihypertensives are associated with an increased fall risk post-discharge); 1,9,10 however, no study has examined the association between *clusters* of medications prescribed at discharge from hospital and the risk of ADEs to our knowledge. A medication cluster refers to groups of medications that a patient is taking concurrently over a given period of time. For example, the co-occurence of psychiatric disorders with diabetes, hypertension, and coronary artery disease within a single patient is common, 11 however, the combined safety of medications to treat these conditions simultaneously (e.g., combination of antihyperglycemics, calcium channel blockers, lipid modifying agents and psychoanaleptics) is not known. 12,13 Indeed, certain combinations of medications can be harmful and may lead to serious drug-drug and drug-condition interactions (e.g., opioids and

gabapentinoids; combination sedatives; anticholinergic burden; combination blood thinners). ^{14,15} Identifying potentially problematic clusters could help guide prescribing decisions in hospital related to re-evaluating newly started therapies as well as potentially deprescribing usual home medications. This could also help identify patients at high risk of ADEs who would benefit from targeted pharmacy specialty support prior to discharge.

Using administrative health data, the primary objective of this study was to characterize medication prescribing patterns at hospital discharge and determine which medication clusters were associated with an increased risk of ADEs in the 30-days post hospital discharge. The secondary objective was to confirm other previously described patient-level factors associated with the occurrence of ADEs .

METHODS

Study design & setting

We conducted a population based retrospective cohort study from March 1, 2016-February 28, 2017, of residents aged 66 years of age or older living in the province of Ontario, Canada. Ontario has a diverse, multicultural population of approximately 2 million people aged 65 years of age or older. All Ontario residents receive universal access to physician and hospital services, and those aged 65 years and up receive medication coverage through a provincial publicly-funded drug insurance program. Ethics approval for data access was obtained from the Ontario Ministry of Health and Trillium Health Partners. Patient consent was not required since the data was fully anonymized.

Data sources

Multiple linked healthcare administrative databases were utilized for this study. Patient demographics and healthcare records were linked using encrypted health card numbers which served as unique and anonymous identifiers across databases. The Ontario Registered Persons Database contains basic demographic information including death. The Ontario Drug Benefits database contains prescription medication claims for all residents aged 65 years or older for medications dispensed to non-hospitalized patients. The Canadian Institutes of Health Information's Discharge Abstract Database and National Ambulatory Care Reporting System contains detailed information for all admissions to hospital and emergency department visits. The Ontario Health Insurance Plan physician claims database contains information on all outpatient services provided by fee-for-service physicians.

Study Population

All Ontario residents aged 66 years or older admitted to hospital between March 1 2016-February 28 2017 were included. If patients were admitted more than once during the study period, only their first hospital episode was considered. We limited the study population to those aged 66 and above as medications are covered under the Ontario Drug Benefits (ODB) program for those aged 65 and above in Ontario, and thus outpatient medication dispensing data is available for this population from 1 year prior to hospitalization. We included only those patients who were discharged to home or to a long term care facility. Patients who were transferred to or from another acute care setting were excluded since we would not have a record of their most recent medication use histories. Additionally, we excluded patients who did not have at least one medication with a valid Anatomical Therapeutic Chemical (ATC) code dispensed in the 30-days following discharge

prior to another healthcare visit. To improve the performance of our clustering algorithm and identify the most clinically relevant clusters, medication classes with a prevalence of less than 1% were excluded (see Appendix Table A1 for list of excluded medications) (Figure 1). Study patients were followed until they were re-hospitalized, visited the emergency department (ED), died from any cause or the study period ended (30-days following index date), whichever occurred first.

Medications dispensed post-hospitalization

Medications dispensed following hospital discharge were measured using prescription claims for medications in the 30-days following hospital discharge. For each dispensed medication, information about the drug identification number (DIN), Anatomical Therapeutic Chemical (ATC code), dispensing date, quantity dispensed and days supply was available. Medications dispensed following a post-discharge healthcare encounter (outpatient visit, ED visit, hospital readmission following index date) were excluded to ensure dispensed medications would capture prescribing decisions made during the index hospital stay alone. This approach was intended to capture medications that were part of the patients' discharge prescription (either newly prescribed or continued from the community prior to the index admission). New medications were defined as those which were not dispensed in the year prior to the index admission and were subsequently dispensed in the 30-days following discharge, while medications continued at hospital discharge were those that were dispensed in the 1-year prior to admission and also dispensed in the 30-days following discharge. Medication class was defined using 3-digit ATC codes¹⁸ and distinct medications within each class were identified according to generic drug name.

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

Patient characteristics potentially associated with ADEs We measured a number of patient characteristics informed by previously published studies on risk factors for ADEs in the hospital and post-discharge setting^{9,19-21} and included: patient demographics (age, sex), health service utilization in the one year prior to hospitalization (number of hospitalizations, ED visits, distinct medications dispensed), pre-admission chronic conditions (identified using ICD-9 & ICD-10 codes; appendix Table A2), number of pre-admission chronic conditions, characteristics of the hospital stay (institution admitted from, reason for admission, main patient service, discharge disposition), the number of medications dispensed overall in the 30-days following discharge as well as the number of new medications. Outcomes The primary outcome for this study was the occurrence of ADEs (identified using ICD-10 codes for ED visits and hospital readmissions; Appendix Table A3)²² in 30-days following the index hospital discharge. Discharge date for the first eligible hospital episode was the index date. STATISTICAL ANALYSIS Descriptive statistics were used to summarize patient characteristics for the entire study cohort. To characterize medication use in the 30-days following discharge, the prevalence of each medication class was calculated (overall and incidence of new use) and the most common drugs in each class were identified. Identification of medication prescribing clusters at hospital discharge was conducted using latent class analysis (LCA). LCA is a model-based method of clustering that identifies unique groups or segments in a population when we do not have a variable that records group

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

membership.²³ Cluster identification was based on medications dispensed 30-days posthospitalization using medication classes (3-digit ATC codes). Each medication class was included as a binary variable at the patient level (patient dispensed a medication in this class yes/no). LCA was performed successively where we started with a single class model under the assumption that all patients were dispensed the same combinations of medications following discharge. Then, increasing numbers of classes were added one at a time. The optimal number of subgroups ("n") was decided by considering the best fit for the data (identified using the Bayesian information criterion [BIC]) and clinical interpretability of each cluster. The best fitting model with n-classes was identified and each patient was assigned to their most likely class based on these model probabilities. The difference in the prevalence of each medication class within a particular cluster vs the prevalence of medication class in the overall population was calculated (e.g., prevalence of patients dispensed diuretics in cluster 1- prevalence of patients dispensed diuretics overall) as was the prevalence of cluster membership among those dispensed each medication class (e.g., number of patients in cluster 1 dispensed diuretics/total number of patients dispensed diuretics). Clinicians on the team reviewed each cluster and agreed upon a clinically meaningful description for each. Patient descriptives were calculated according to medication cluster membership. The crude risk of ADEs were calculated overall and for each cluster separately. Multivariable logistic regression models were constructed to assess the potential

Multivariable logistic regression models were constructed to assess the potential association between membership to a particular medication cluster and ADEs post-discharge, while also evaluating other patient characteristics historically associated with ADEs. The binary outcome was the occurrence of at least one ADE in the 30-days following discharge. Both cluster membership and patient characteristics were included as covariates in the same model. Six separate logistic models were constructed where a binary variable was included for each cluster separately

in order to obtain the adjusted risk associated with belonging to a given cluster compared to all other clusters. Adjusted odds ratios and 95% confidence intervals were obtained for each covariate in the logistic regression model.

Sensitivity analysis

While ICD-10 code sets to identify ADE's have high specificity, they only have a sensitivity of up to 28%. ^{24–26} All cause events will capture events that medications likely did not contribute to (e.g., pneumonia, sepsis, urinary tract infection), however, ADEs can also manifest as worsening of a patient's underlying disease (e.g., statin non-adherence and occurrence of stroke)²⁷ which would not be coded as being medication related. Therefore, in order to confirm the robustness of our results, and capture adverse events that were not necessarily coded as drug related, we reconducted our primary analysis using a composite outcome of all cause emergency department visits or mortality in 30-days.

RESULTS

Overall, 837,655 patients were admitted to hospital in Ontario between March 1 2016 and February 28 2017. After excluding those who were younger than 66 (n=544,064; 65%), those who were admitted from another acute care facility (n=10,720; 1%), and patients who did not have eligible medications dispensed 30-days post discharge prior to another healthcare encounter (n=84,539; 10%), 188,354 patients were included in the study cohort (Figure 1).

Median age (IQR) of the study participants was 77 (71-84) years and 53% were female. In the 1-year prior to the index hospital stay, 18% of patients had at least one hospitalization, patients had a median (IQR) of 2 (1-3) ED visits, 9 (6-13) medications dispensed, and 2 (1-3) chronic conditions. The most common chronic conditions included cancer (32% of patients), diabetes

(26%) and osteoarthritis (25%). Most patients were admitted from the community and were not receiving home care (84%), 11% were admitted from long-term care and 5% were admitted from an outpatient clinic. The most common services patients were admitted to included general medicine (43%), orthopedic surgery (15%), general surgery (10%) and cardiology (8%). In the 30-days following discharge, a median (IQR) of 3 medications (2-6) were dispensed overall and 79% of patients had at least one new medication dispensed (Table 1). The top 5 most common medication classes (including new and continued medications) included: analgesics (40% prevalence, most common were hydromorphone and oxycodone), antithrombotics (30% prevalence, most common warfarin and clopidogrel), lipid modifying agents (25% prevalence, most common atorvastatin), drugs for acid related disorders (24% prevalence, most common ciprofloxacin, cefalexin, amoxicillin clavulanic acid cefuroxime) (Table 2).

Goodness of fit statistics indicated that the study population consisted of 6 separate clusters of medication dispensing patterns. **Cluster 1** ("cardiovascular" cluster, n=25,995; 14% of study cohort) was characterized by use of beta blocking agents (e.g., metoprolol), cholesterol lowering agents (e.g., atorvastatin), antithrombotics (e.g., warfarin, clopidogrel), agents acting on the renin angiotensin system (e.g., ramipril, perindopril) and cardiac therapy (e.g., digoxin, nitroglycerin). Patients in this cluster were more likely to be male, had a higher prevalence of acute myocardial infarction, arrhythmia, heart failure and coronary artery syndrome, were more likely to be admitted from home without homecare, to be admitted for a circulatory related diagnosis, and receive care on a cardiology unit (Table 1). **Cluster 2** ("respiratory" cluster, n=47,747; 26%) was characterized by use of corticosteroids for systemic use (e.g., prednisone) drugs for obstructive airway diseases (e.g., salbutamol) and antivirals for systemic use (e.g., oseltamivir). Patients in this

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

cluster had a higher prevalence of COPD and were more likely to have been admitted for a respiratory related diagnosis and to receive care on a general medicine unit (Table 1). Cluster 3 ("complex care needs" cluster, n=22,147; 12%) was characterized by use of antidepressants (e.g., trazodone, escitalopram) antipsychotics (e.g., quetiapine, risperidone), drugs for acid related disorders (e.g., pantoprazole), gabapentinoids (e.g., gabapentin, pregabalin), analgesics (e.g., hydromorphone, oxycodone), drugs for constipation (e.g., docusate), thyroid therapy (e.g., levothyroxine) and anti-parkinson's drugs (e.g., carbidopa/levodopa). Patients in this cluster were more likely to be female, had a greater number of medications dispensed prior to admission, were more likely to have dementia, any mental health disorder, or mood/anxiety disorder, were more likely to have been admitted from long term care, be admitted for a mental health, nervous system or injury related diagnosis and were most likely to receive care on a general medicine unit. (Table 1) Cluster 4 ("cardiovascular and metabolic"; n=28,924, 15%) was characterized by use of cholesterol lowering agents, beta blocking agents, drugs for acid related disorders, diuretics (e.g., furosemide), agents acting on the renin-angiotensin system, drugs used in diabetes (e.g., metformin), calcium channel blockers (e.g., amlodipine), antipsychotics, anti-thrombotics, antigout preparations (e.g., allopurinol) and other anti-hypertensives (e.g., hydralazine). Patients in this cluster had more medications dispensed prior to admission, were more likely to have cardiovascular conditions, diabetes and renal disease, be admitted from long term care, be admitted for a circulatory related diagnosis, be on a general medicine or cardiology unit and had a high proportion of multiple new medications dispensed. (Table 1) Cluster 5 ("infection" cluster; n=17,867, 10%) was characterized by use of antibacterials for systemic use (e.g., ciprofloxacin, cefalexin, amoxicillin & beta-lactamase inhibitors) and anti-fungals (e.g., metronidazole). Patients in this cluster were more likely to be male, have cancer, be admitted from home without homecare

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

and be admitted for a malignancy, respiratory or digestive related diagnosis (Table 1). Cluster 6 ("surgical" cluster; n=45,684, 24%) was characterized by use of analgesics, anti-thrombotics, drugs for constipation and anti-inflammatory products (e.g., celecoxib, meloxicam). Patients in this cluster were slightly younger, more likely to have osteoarthritis and arthritis, be admitted from home, be admitted for a malignancy, or musculoskeletal related diagnosis, and be on an orthopedic surgery unit (Table 1). Overall, 12,680 (6.7%) patients had an ADE in the 30-days following discharge. The most common diagnosis associated with ADEs across the majority of clusters was acute kidney failure and volume depletion. Of note, enterocolitis due to Clostridium difficile was a common ADE in cluster 5 (infection) and pulmonary embolism in the absence of acute cardiorespiratory disease was common in cluster 6 (surgical). Crude risk of ADEs was highest for those in cluster 4 (cardiovascular and metabolic; 8.9%) and lowest for those in cluster 6 (surgical; 4.6%) (Table 3). Our multivariable model included both variables indicating cluster membership as well as patient level variables, therefore, the interpretation of the odds ratio for a given covariate in the model is the risk of ADE's associated with presence of a characteristic (vs reference) after accounting for the other patient characteristics included in the model. After considering other patient characteristics, those in the respiratory cluster had the highest risk of ADEs (adjusted odds ratio [aOR]: 1.12, 95% CI: 1.08-1.17) compared to all the other clusters while those in the neurocognitive & complex care needs cluster had the lowest risk (aOR:0.82, 95% CI: 0.77-0.87). There was no difference in the risk of ADEs among patients in the cardiovascular, metabolic syndrome, infection and surgical clusters when comparing each cluster to all other clusters. (Table 3)

Patient level factors that were also associated with an increased risk of ADEs included age, increasing healthcare service use in the year prior to admission (hospitalizations and ED visits), a greater number of pre-admission medications dispensed, presence of heart failure, arrhythmia, renal disease and liver disease, being admitted from long term care, being admitted from the ED, increasing length of stay, a higher Charlson Comorbidity Score, and a greater number of new medications dispensed in the 30-days following discharge (Table 3). Of all the variables in the model, belonging to the respiratory cluster, presence of renal disease, liver disease and heart failure were associated with the highest risk of ADEs.

Our sensitivity analyses indicated that the direction of the point estimates for the association between the characteristics included in our multivariable model and ED visits/mortality was similar when compared to the primary analysis. However, the magnitude of these associations was higher for the infection and surgical clusters. (Appendix Table A5).

DISCUSSION

In this population-based retrospective cohort study of older hospitalized adults, we identified 6 clusters of medication prescribing patterns at hospital discharge; cardiovascular, respiratory, complex care needs, metabolic syndrome, infection and surgical clusters. After accounting for other factors known to increase the risk of ADE after discharge, patients in the respiratory cluster had the highest risk of an ADE after discharge while those in the complex care needs cluster had the lowest risk. We also confirmed that a number of previously reported patient characteristics were associated with an increased risk of ADEs, for example, the overall number of medications, the addition of new medications, as well as the presence of heart failure, renal disease and liver disease.

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

A systematic review published in 2018 aimed to determine risk factors for medication related harm among older adults after hospital discharge. 1 Only 3 of the 8 included studies conducted multivariable analyses to evaluate risk factors for medication-related harm. Among these studies, only select medication classes (as opposed to combinations or clusters of medication classes) and diagnoses were included in the multivariable analyses. The majority of studies were of moderate quality and substantial methodological heterogeneity was identified with respect to how related harm was measured. A higher absolute number of medications, 28,29 the addition of new medications at discharge,³⁰ warfarin^{28,29}, furosemide³¹, a lower Mini-Mental State Examination score³⁰ and female sex³⁰ were all independent risk factors for medication harm following hospitalization. Since this systematic review was published, three other studies have evaluated risk factors for medication-related harm following a hospital stay.^{2,9,32} Risk factors from these studies included the number of medication changes, prior hospitalizations preceding the index admission, older age, past adverse drug reaction(s), prescriptions for antiplatelet drugs, antidiabetic drugs, corticosteroids and again, a higher absolute number of medications were risk factors. Consistent risk factors for an increased risk of ADEs post hospital discharge are older age, the absolute number of medications and the addition of new medications at discharge, which we also confirmed in our analysis. However, we found no other study that specifically evaluated medication clusters or combinations of medications as an independent risk factor for ADEs post discharge.

The results of this study inform clinical practice in two important ways. First, this study provides evidence that medications tend to be prescribed in readily identifiable, predictable medication clusters. Furthermore, some clusters differentially impact the risk of post hospital ADEs independent of patient characteristics and the number of prescribed medications. Therefore,

these results could inform clinicians about new potentially modifiable risk factors for ADEs, such as newly added combinations of medications, which may be important to review prior to the patient being discharged. For example, in the respiratory cluster, patients were most likely to be using a combination of corticosteroids, drugs for obstructive airway diseases and antivirals, and patients in this cluster also had the highest independent risk of ADEs post-discharge. Thus, medications prescribed to patients in this cluster (especially new medications) may be important to review prior to discharge, or patients may require counseling with respect to expected or predictable side effects from this medication cluster (e.g., gastrointestinal symptoms from systemic corticosteroids and oseltamivir, or delirium from combinations of anticholinergic inhalers and corticosteroids).

Second, similar to previous studies, better understanding of non-modifiable patient-level factors associated with an increased risk of ADEs in the 30-days post discharge (e.g., older age, presence of heart failure etc.) can inform clinicians which patients may benefit most from resource-intensive interventions to decrease ADEs (e.g., home care post discharge or targeted education related to signs and symptoms to monitor for related to a potential ADE.) For example, presence of heart failure, renal disease or liver disease could be important markers for patients at high risk of experiencing an ADE and should have their medications reviewed by a pharmacist prior to discharge. Interestingly, although the neurocognitive & complex care needs cluster was associated with the highest crude risk of ADEs, after considering other patient characteristics, this cluster was not associated with an increased risk of ADEs compared to any of the other clusters. This could indicate that these patients may be well known to be "high risk" and are receiving adequate support with respect to their medications in the post discharge period. A limitation of our study is that we did not have information on factors such as involvement of a pharmacist or consultation with geriatrics prior to discharge.

There are other limitations associated with this study that are important to keep in mind. First, although patients were dispensed particular medications, they might not have taken these medications as prescribed. This is a limitation associated with all studies which use dispensing data to capture drug exposure. Second, we did not have access to clinical data to include in our models (e.g., renal function, sodium levels) which may have led to unmeasured confounding. Third, the data analyzed in this study was from 2016/2017 and the prescribing patterns for certain medications have changed over this time period. For example, the use of direct oral anticoagulants has increased dramatically in the past 5 years. Lastly, although we analyzed both ADEs and emergency department visits as outcomes and found consistent results between the two models, it's still important to acknowledge that use of ICD10 codes to measure ADEs will miss many outcomes which are drug related and ED visits will also capture a number of events which are not related to medications. Additional research is required with respect to valid measures of ADEs using administrative health data.

Despite these limitations, this study is an important step towards personalized medicine as it relates to appropriate prescribing. Identifying patients who are taking high risk clusters of medications could lead to interventions that improve the safety of medication use following hospitalization. By considering a patient's whole drug regimen, in combination with their characteristics, we can take steps towards a more holistic approach to prescribing, not just focusing on treating single conditions or addressing single high risk drug classes in isolation.

In conclusion, this study suggests that ADEs post hospital discharge are linked to identifiable clusters of medications, in addition to non-modifiable patient characteristics, such as age and certain comorbidities. This information may help clinicians and researchers better

understand what patient populations and which types of interventions may benefit patients, to reduce their risk of experiencing an ADE.

STATEMENTS AND DECLARATIONS Conflict of Interest: Dr. McDonald receives salary support for research from the Fond de recherche santé Québec and is the owner and chief scientific officer of MedSafer, a software that helps guide clinicians through the process of deprescribing for older adults with polypharmacy (the intellectual property is jointly held with McGill University). Authors have no other competing interests to disclose. **Author Contributions** Conceptualization - DW; Methodology - DW; Validation - DW, EGM; Formal Analysis - DW, XM; Investigation - All authors; Resources - DW, WPW; Data Curation - WPW; Writing -Original Draft - DW, EGM, LLS, TT, LM; Writing - Review and Editing - All authors; Visualization DW, EGM **Sponsors Role:** N/A

REFERENCES


494 495 496

497

- 1. Parekh N, Ali K, Page A, Roper T, Rajkumar C. Incidence of Medication-Related Harm in Older Adults After Hospital Discharge: A Systematic Review. *J Am Geriatr Soc.* 2018;66:1812–1822.
- Uitvlugt EB, Janssen MJA, Siegert CEH, Kneepkens EL, van den Bemt BJF, van den Bemt PMLA,
 Karapinar-Çarkit F. Medication-Related Hospital Readmissions Within 30 Days of Discharge:
 Prevalence, Preventability, Type of Medication Errors and Risk Factors. Front Pharmacol.
 2021:12:567424.
- Weir DL, Lee TC, McDonald EG, Motulsky A, Abrahamowicz M, Morgan S, Buckeridge D,
 Tamblyn R. Both New and Chronic Potentially Inappropriate Medications Continued at Hospital
 Discharge Are Associated With Increased Risk of Adverse Events. *J Am Geriatr Soc* [Internet].
 [cited 2020 Mar 31];n/a. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/jgs.16413
- Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF,
 Hallisey R. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. *JAMA*. 1995;274:29–34.
- 5. Tamblyn R, Abrahamowicz M, Buckeridge DL, Bustillo M, Forster AJ, Girard N, Habib B, Hanley
 J, Huang A, Kurteva S, Lee TC, Meguerditchian AN, Moraga T, Motulsky A, Petrella L, Weir DL,
 Winslade N. Effect of an Electronic Medication Reconciliation Intervention on Adverse Drug
 Events: A Cluster Randomized Trial. JAMA Netw Open. 2019;2:e1910756–e1910756.
- Harris CM, Sridharan A, Landis R, Howell E, Wright S. What Happens to the Medication Regimens of Older Adults During and After an Acute Hospitalization?: *J Patient Saf.* 2013;9:150–153.
- 7. Viktil KK, Blix HS, Eek AK, Davies MN, Moger TA, Reikvam A. How are drug regimen changes during hospitalisation handled after discharge: a cohort study. *BMJ Open.* 2012;2:e001461.
- Weir DL, Motulsky A, Abrahamowicz M, Lee TC, Morgan S, Buckeridge DL, Tamblyn R.
 Challenges at Care Transitions: Failure to Follow Medication Changes Made at Hospital Discharge.
 Am J Med [Internet]. 2019 [cited 2019 Jul 10]; Available from:
 https://linkinghub.elsevier.com/retrieve/pii/S0002934319304309
- Parekh N, Ali K, Davies JG, Stevenson JM, Banya W, Nyangoma S, Schiff R, Cammen T van der, Harchowal J, Rajkumar C. Medication-related harm in older adults following hospital discharge: development and validation of a prediction tool. *BMJ Qual Saf* [Internet]. 2019 [cited 2019 Dec
 4];Available from: http://qualitysafety.bmj.com/content/early/2019/09/16/bmjqs-2019-009587
- 527 10. Stevenson JM, Williams JL, Burnham TG, Prevost AT, Schiff R, Erskine SD, Davies JG. Predicting
 528 adverse drug reactions in older adults; a systematic review of the risk prediction models [Internet].
 529 Clin. Interv. Aging. 2014 [cited 2019 Dec 8]; Available from:
- https://www.dovepress.com/predicting-adverse-drug-reactions-in-older-adults-a-systematic-review-peer-reviewed-fulltext-article-CIA
- 532 11. Boyd CM; L B; Weiss, C; Wolff, J; Clark, R; Richards, T. Multimorbidity Pattern Analyses and Clinical Opportunities: Diabetes. *Faces Medicaid Data Ser.* 2010;
- 534 12. Mutasingwa DR, Ge H, Upshur REG. How applicable are clinical practice guidelines to elderly patients with comorbidities? *Can Fam Physician Med Fam Can.* 2011;57:e253-262.
- Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. *Int J Chron Obstruct Pulmon Dis.* 2015;10:95–109.
- McDonald EG, Wu PE, Rashidi B, Forster AJ, Huang A, Pilote L, Papillon-Ferland L, Bonnici A,
 Tamblyn R, Whitty R, Porter S, Battu K, Downar J, Lee TC. The MedSafer Study: A Controlled
 Trial of an Electronic Decision Support Tool for Deprescribing in Acute Care. *J Am Geriatr Soc.* 2019;67:1843–1850.
- Zerah L, Henrard S, Wilting I, O'Mahony D, Rodondi N, Dalleur O, Dalton K, Knol W, Haschke
 M, Spinewine A. Prevalence of drug-drug interactions in older people before and after hospital

- admission: analysis from the OPERAM trial. *BMC Geriatr*. 2021:21:571.
- Living and Dying in Ontario: An Opportunity to Improve Health Information [Internet]. [cited 2021
 May 24]; Available from: https://www.ices.on.ca/Publications/Atlases-and-Reports/2008/Living-and-dying-in-Ontario
- Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. *Can J Clin Pharmacol J Can Pharmacol Clin*.
 2003;10:67–71.
- 551 18. WHOCC ATC/DDD Index [Internet]. [cited 2021 May 4]; Available from: https://www.whocc.no/atc_ddd_index/
- 553 19. Gallagher PF, O'Connor MN, O'Mahony D. Prevention of Potentially Inappropriate Prescribing for
 554 Elderly Patients: A Randomized Controlled Trial Using STOPP/START Criteria. *Clin Pharmacol* 555 Ther. 2011;89:845–854.
- Nair NP, Chalmers L, Connolly M, Bereznicki BJ, Peterson GM, Curtain C, Castelino RL,
 Bereznicki LR. Prediction of Hospitalization due to Adverse Drug Reactions in Elderly
 Community-Dwelling Patients (The PADR-EC Score). *PLOS ONE*. 2016;11:e0165757.
- O'Connor MN, O'Sullivan D, Gallagher PF, Eustace J, Byrne S, O'Mahony D. Prevention of
 Hospital-Acquired Adverse Drug Reactions in Older People Using Screening Tool of Older
 Persons' Prescriptions and Screening Tool to Alert to Right Treatment Criteria: A Cluster
 Randomized Controlled Trial. J Am Geriatr Soc. 2016;64:1558–1566.
- Hohl CM, Karpov A, Reddekopp L, Stausberg J. ICD-10 codes used to identify adverse drug events in administrative data: a systematic review. *J Am Med Inform Assoc JAMIA*. 2014;21:547–557.
- 565 23. MacDonald K. Latent Class Analysis (LCA) in Stata. :58.

- Hohl CM, Kuramoto L, Yu E, Rogula B, Stausberg J, Sobolev B. Evaluating adverse drug event reporting in administrative data from emergency departments: a validation study. *BMC Health Serv Res* [Internet]. 2013 [cited 2019 Jan 23];13. Available from: https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-473
- 570 25. Honigman B, Lee J, Rothschild J, Light P, Pulling RM, Yu T, Bates DW. Using computerized data to identify adverse drug events in outpatients. *J Am Med Inform Assoc JAMIA*. 2001;8:254–266.
- 572 26. Field TS, Gurwitz JH, Harrold LR, Rothschild JM, Debellis K, Seger AC, Fish LS, Garber L,
 573 Kelleher M, Bates DW. Strategies for Detecting Adverse Drug Events among Older Persons in the
 574 Ambulatory Setting. *J Am Med Inform Assoc JAMIA*. 2004;11:492–498.
- Ravn-Nielsen LV, Duckert M-L, Lund ML, Henriksen JP, Nielsen ML, Eriksen CS, Buck TC,
 Pottegård A, Hansen MR, Hallas J. Effect of an In-Hospital Multifaceted Clinical Pharmacist
 Intervention on the Risk of Readmission: A Randomized Clinical Trial. *JAMA Intern Med*.
 2018;178:375–382.
- 579 28. Hanlon JT, Pieper CF, Hajjar ER, Sloane RJ, Lindblad CI, Ruby CM, Schmader KE. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. *J Gerontol A Biol Sci Med Sci*. 2006:61:511–515.
- Letrilliart L, Hanslik T, Biour M, Fagot JP, Guiguet M, Flahault A. Postdischarge adverse drug
 reactions in primary care originating from hospital care in France: a nationwide prospective study.
 Drug Saf. 2001;24:781–792.
- 585 30. Gray SL, Mahoney JE, Blough DK. Adverse drug events in elderly patients receiving home health services following hospital discharge. *Ann Pharmacother*. 1999;33:1147–1153.
- 587 31. Marusic S, Sicaja M, Obreli Neto PR, Franic M, Marinovic I, Bacic-Vrca V. Adverse drug reactions 588 in elderly patients following discharge from an internal medicine clinic. *Int J Clin Pharmacol Ther*. 589 2014;52:906–913.
- Aubert CE, Rodondi N, Netzer S, Dalleur O, Spinewine A, Maanen CD, Knol W, O'Mahony D,
 Aujesky D, Donzé J. Predictors of 1-year drug-related admissions in older multimorbid hospitalized
 adults. J Am Geriatr Soc [Internet]. [cited 2022 Jan 27];n/a. Available from:
 https://onlinelibrary.wiley.com/doi/abs/10.1111/jgs.17667



N=188,354 patients 66 years of age and older discharged home or to long term care with eligible dispensed medications in the 30-days following hospital discharge prior to another healthcare encounter

Table 1. Patient characteristics overall and according to cluster

Demographics	Overell	Cluster 1	Cluster 2	Cluster 3	Cluster 4	Cluster 5	Cluster 6
	(n=188,354)	Cardio (n=25,995)	Respiratory (n=47,737)	Complex care needs (n=22,147)	Cardio- Vascular and metabolic (n=28,924)	Infection (n=17,867)	Surgical (n=45,684)
Age, median (IQR)	77 (71-84)	77 (71-84)	78 (71-84)	81 (74-88)	81 (74-87)	75 (70-81)	73 (69-79)
66-75	83,885 (44.5)	11,275 (43.4)	19,583 (41.0)	6,711 (30.3)	8,503 (29.4)	9,261 (51.8)	28,552 (62.5)
76-85	61,692 (32.8)	8,801 (33.9)	16,291 (34.1)	7,272 (32.8)	10,579 (36.6)	5,845 (32.7)	12,904 (28.3)
85+	42,777 (22.7)	5,919 (22.8)	11,863 (24.9)	8,164 (36.9)	9,842 (34.0)	2,761 (15.5)	4,228 (9.3)
Sex							
Male	88,717 (47.1)	14,032 (54.0)	22,919 (48.0)	7,607 (34.4)	13,050 (45.1)	10,424 (58.3)	20,685 (45.3)
Female	99,637 (52.9)	11,963 (46.0)	24,818 (52.0)	14,540 (65.7)	15,874 (54.9)	7,443 (41.7)	24,999 (54.7)
Health services 1-year prior to							
admission							
Hospitalizations, mean (SD)	0.3 (0.7)	0.2(0.6)	0.3(0.8)	0.4(0.9)	0.5(0.9)	0.3 (0.7)	0.2(0.5)
0	153,601 (81.6)	22,002 (84.6)	38,747 (81.2)	16,774 (75.7)	21,174 (73.2)	14,826 (83.0)	40,078 (87.3)
1	23,792 (12.6)	2,937 (11.3)	6,011 (12.6)	3,497 (15.8)	4,821 (16.7)	2,117 (11.9)	4,409 (9.7)
2	6,854 (3.6)	702 (2.7)	1,868 (3.9)	1,149(5.2)	1,714 (5.9)	582 (3.3)	839 (1.8)
3	2,342 (1.2)	214(0.8)	615 (1.3)	424 (1.9)	662 (2.3)	194(1.1)	233 (0.5)
4+	1,765 (0.9)	140(0.5)	4 (1.0)	303 (1.4)	553 (1.9)	148 (0.8)	125(0.3)
Emergency department visits, median (IOR)	2 (1-3)	2 (1-3)	2 (1-4)	2 (1-4)	2 (1-4)	2 (1-4)	1 (0-2)
0	20,205 (10.7)	1,327 (5.1)	1,584 (3.3)	768 (3.5)	886 (3.1)	1,013 (5.7)	14,628 (32.0)
1	61,425 (32.6)	10,785 (41.5)	15,836 (33.2)	6,867 (31.0)	8,893 (30.8)	5,655 (31.7)	13,389 (29.3)
2	38,629 (20.5)	5,839 (22.5)	10,489 (22.0)	4,924 (22.2)	6,346 (21.9)	3,832 (21.5)	7,199 (15.8)
3	23,781 (12.6)	3,362 (12.9)	6,689 (14.0)	3,259 (14.7)	4,171 (14.4)	2,396 (13.4)	3,904 (8.6)
4	14,099 (7.5)	1,706 (6.6)	3,946 (8.3)	2,073 (9.4)	2,819 (9.8)	1,440(8.1)	2,115 (2.6)
5	8,387 (4.5)	974 (3.8)	2,439 (5.1)	1,226 (5.5)	1,685 (5.8)	893 (5.0)	1,170 (2.6)
6+	21,828 (11.6)	2,002 (7.7)	6,754 (14.2)	3,030 (13.7)	4,124 (14.3)	2,638 (14.8)	3,280 (7.2)
Distinct medications dispensed,	9 (6-13)	7 (5-11)	9 (6-13)	11 (8-15)	13 (9-17)	8 (5-12)	7 (4-10)
median (IQR)							
0	3,838 (2.0)	893 (3.4)	906 (1.9)	215 (1.0)	166 (0.6)	432 (2.4)	1,226 (2.7)
1-3	18,830 (10.0)	3,507 (13.5)	4,529 (9.5)	678 (3.1)	415 (1.4)	2,201 (12.3)	7,500 (16.4)
4-6	36,480 (19.4)	6,233 (24.0)	9,662 (20.2)	2,721 (12.3)	1,930 (6.7)	3,842 (21.5)	12,092 (26.5)
7-9	42,226 (22.4)	6,584 (25.3)	11,090 (23.2)	4,850 (21.9)	4,842 (16.7)	4,050 (22.7)	10,810 (23.7)
10-12	35,485 (18.8)	4,488 (17.3)	9,212 (19.3)	4,895 (22.1)	6,581 (22.8)	3,212 (18.0)	7,097 (15.5)

Long term care	Community, home care	Community, no home care	Institution admitted from	Index Admission Characteristics	6+	5	4	3	2	1	0	Median (IQR)	Number of Chronic Conditions	Liver disease	Renal disease	Rheumatoid arthritis	Arthritis	Osteoarthritis	Osteoporosis	Mood and anxiety disorders	Mental health disorders	Dementia	Asthma	disease	Chronic obstructive pulmonary	Diabetes	Cancer	Stroke	Hypertension	Coronary artery syndrome	Heart failure	Arrythmia	Acute myocardial infarction	Chronic Conditions	16+	13-15
20,326 (10.8)	793 (0.4)	157,729 (83.7)			7,693 (4.1)	11,745 (6.2)	24,319 (12.9)	41,707 (22.1)	52,236 (27.7)	39,302 (20.9)	11,351 (6.0)	~ (1 °)	2,002 (1.1)	2 002 (1 1)	17,811 (9.5)	5,682 (3.0)	30,588 (16.2)	47,504 (25.2)	7,752 (4.1)	31,411 (16.7)	15,778 (8.4)	24,366 (12.9)	9,450 (5.0)		22,586 (12.0)	49,296 (26.2)	60.711 (32.3)	13,757 (7.3)	64,884 (34.5)	36,460 (19.4)	25,163 (13.4)	31,438 (16.7)	9,082 (4.8)		27,258 (14.5)	24,237 (12.9)
1,330 (5.1)	70 (0.3)	22,348 (86.0)			1,108 (4.3)	1,823 (7.0)	3,911 (15.1)	6,346 (24.4)	7,163 (27.6)	4,654 (17.9)	990 (3.8)	0 (10)	3 (7-3)	167 (0.6)	2,337 (9.0)	259(2.0)	3,190 (12.3)	4,270 (16.4)	827 (3.2)	3,119 (12.0)	1,626 (6.3)	1,951 (7.5)	929 (3.6)	-3 (: :-)	1.866 (7.2)	7,028 (27.0)	6,909 (26.6)	3,322 (12.8)	9,742 (37.5)	8,854 (34.1)	5,315 (20.5)	7,165 (27.6)	4,048 (15.6)		1,863 (7.2)	2,427 (9.3)
3,806 (8.0)	227 (0.5)	41,036 (86.0)			1,839 (3.9)	2,835 (5.9)	5,740 (12.0)	10,028 (21.0)	12,915 (27.1)	10,787 (22.6)	3,593 (7.5)	E (10)	2 (1-3)	750 (1.6)	5,328 (11.2)	1,377 (2.9)	6,487 (13.6)	7,225 (15.1)	2,003 (4.2)	7,905 (16.6)	3,959 (8.3)	5,763 (12.1)	2,996 (6.3)	-) ()	8.066 (16.9)	12,004 (25.2)	15,974 (33.5)	3,113 (6.5)	15,468 (32.4)	7,903 (16.6)	6,527 (13.7)	8,048 (16.9)	1,390 (2.9)		6,352 (13.3)	5,986 (12.5)
7,102 (32.1)	174 (0.8)	13,847 (62.5)			825 (3.7)	1,311 (5.9)	2,566 (11.6)	4,539 (20.5)	5,869 (26.5)	5,375 (24.3)	1,662 (7.5)	2 (1 2)	2 (1-3)	204 (0 9)	1,708 (7.7)	717 (3.2)	3,000 (13.6)	4,354 (19.7)	992 (4.5)	6,162 (27.8)	2,985 (13.5)	7,502 (33.9)	944 (4.3)	-9 ()	2.959 (13.4)	3,920 (17.7)	5,840 (26.4)	1,855 (8.4)	5,630 (25.4)	2,324 (10.5)	2,013 (9.1)	2,392 (10.8)	412 (1.9)		4,890 (22.1)	3,898 (17.6)
6,118 (21.2)	190 (0.7)	21,188 (73.4)			2,443 (8.5)	2,910 (10.1)	4,954 (17.1)	6,589 (22.8)	6,739 (23.3)	4,266 (14.8)	1,023 (3.5)	5 (1 1)	3 (7.4)	333 (1 2)	4,646 (16.1)	749 (2.6)	4,003 (13.8)	5,081 (17.6)	929 (3.2)	5,180 (17.9)	2,694 (9.3)	5,804 (20.1)	1,511 (5.2)	., ()	4.139 (14.3)	12,257 (42.4)	7,172 (24.8)	3,201 (11.1)	9,531 (33.0)	7,775 (26.9)	7,990 (27.6)	6,732 (23.3)	2,335 (8.1)		8,959 (31.0)	6,031 (20.9)
602 (3.4)	56 (0.3)	16,286 (91.2)			474 (2.7)	768 (4.3)	1,773 (9.9)	3,352 (18.8)	5,136 (28.8)	4,623 (25.9)	1,741 (9.7)	r (1 0)	2 (1-3)	195 (1 1)	1,539 (8.6)	466 (2.6)	2,526 (14.1)	2,708 (15.2)	713 (4.0)	2,493 (14.0)	1,270 (7.1)	1,152 (6.5)	1,073 (6.0)	-3	2,774 (15.5)	4,472 (25.0)	7,324 (41.0)	573 (3.2)	5,908 (33.1)	2,548 (14.3)	1,329 (7.4)	2,162 (12.1)	248 (1.4)		2,093 (11.7)	2,037 (11.4)
1,368 (3.0)	76 (0.2)	43,024 (94.2)			1,004 (2.2)	2,098 (4.6)	5,375 (11.8)	10,853 (23.8)	14,414 (31.6)	9,597 (21.0)	2,343 (5.1)	2 (1 2)	2 (1-3)	353 (0.8)	2,253 (4.9)	1,844 (4.0)	11,382 (24.9)	23,866 (52.2)	2,288 (5.0)	6,552 (14.3)	3,244 (7.1)	2,194 (4.8)	1,997 (4.4)	-9: (-:-)	2.782 (6.1)	9,615 (21.1)	17,492 (38.3)	1,693 (3.7)	18,605 (40.7)	7,056 (15.5)	1,989 (4.4)	4,939 (10.8)	649 (1.4)		3,101 (6.8)	3,858 (8.4)

Urology	Traumatology	Thoracic Surgery	Orthopaedic Surgery	Neurosurgery	Cardio Surgery	General Surgery	Respirology	Neurology	Nephrology	Gastro-Enterology	Cardiology	General Medicine	General Practice	Main Patient Service	Total LOS, median (IQR)	Unspecified	Health services	Injury	Congenital	Genitourinary	Musculoskeletal	Skin	Digestive	Respiratory	Circulatory	Ear	Eye	Nervous System	Mental Health	Endocrine	Neoplasm	Infection	(Most responsible diagnosis)	Unclassified	Ambulatory care
8,315 (4.4)	1,992 (1.1)	1,147(0.6)	27,229 (14.5)	1,703 (0.9)	5,878 (3.1)	19,048 (10.1)	6,706 (3.6)	2,877 (1.5)	1,461 (0.8)	4,949 (2.6)	15,882 (8.4)	80,133 (42.5)	2,228 (1.2)		4 (2-8)	11,187 (5.9)	4,274 (2.3)	15,414 (8.2)	106 (0.1)	12,396 (6.6)	28,406 (15.1)	2,060 (1.1)	17,820 (9.5)	23,255 (12.4)	37,963 (20.2)	448 (0.2)	141(0.1)	3,292 (1.8)	4,623 (2.5)	4,984 (2.7)	14,031 (7.5)	6,054 (3.2)		340 (0.2)	9,166 (4.9)
372 (1.4)	ı	ı	1,267 (4.9)	ı	2,017 (7.8)	1,218 (4.7)	257 (1.4)	985 (3.8)	ı	385 (1.5)	7,335 (28.2)	10,944 (42.1)	-		4 (2-8)	1,517(5.8)	487 (1.9)	1,126 (4.3)	24(0.1)	790 (3.0)	1,188 (4.6)	96(0.4)	1,339 (5.2)	1,189 (4.6)	15,403 (59.3)	66(0.3)	28(0.1)	637 (2.5)	328(1.3)	488 (1.9)	667 (2.3)	455 (1.8)		33 (0.1)	2,214 (8.5)
1,617 (3.4)	1	ı	1,552 (3.3)	534 (1.1)	771 (1.6)	3,728 (7.8)	2,729 (5.7)	662 (1.4)	554 (1.2)	2,068 (4.3)	3,174 (6.7)	26,128 (54.7)	-		4 (2-8)	4,035 (8.6)	1,081(2.3)	2,911 (6.1)	19 (-)	3,349 (7.0)	1,905 (4.0)	600 (1.3)	6,311 (13.2)	9,156 (19.2)	7,335 (15.4)	189(0.4)	49 (0.1)	993 (2.1)	1,350(2.8)	1,871 (3.9)	3,669 (7.7)	2,103 (4.4)		86 (0.2)	2,582 (5.4)
529 (2.4)	458 (2.1)		2,282 (10.3)	1	244 (1.1)	1,323 (6.0)	916 (4.1)	353 (1.6)	1	567 (2.6)	452 (2.0)	13,083 (59.1)	497 (2.2)		6 (3-13)	1,732 (7.8)	597 (2.7)	3,279 (14.8)	9 (-)	1,666 (7.5)	1,823 (8.2)	344 (1.6)	1,921 (8.7)	3,469 (15.7)	1,943 (8.8)	44 (0.2)	14 (0.1)	741 (3.4)	1,626 (7.3)	614 (2.8)	1,102(5.0)	1,001 (4.5)		101 (0.5)	923 (4.2)
692 (2.4)	228 (1.2)	ı	1,862 (6.4)		1,374 (4.8)	1,373 (4.8)	1,254 (4.3)	553 (1.9)	367 (1.3)	701 (2.4)	3,369 (11.7)	15,620 (54.0)	425 (1.5)		6 (3-10)	2,011 (7.0)	479 (1.7)	2,471 (8.5)	11 (-)	1,936 (6.7)	1,703 (5.9)	373 (1.3)	1,924 (6.7)	4,305 (14.9)	8,762 (30.3)	70 (0.2)	13 (-)	513 (1.8)	921 (3.2)	1,125 (3.9)	874 (3.0)	1,126(3.9)		83 (0.3)	1,345 (4.7)
1		1	452 (2.5)	1		2,371 (13.3)	1,170 (6.6)		1	621 (3.5)	1	7,736 (43.3)	212 (1.2)		3 (2-5)	827 (4.6)	380 (2.1)	850 (4.8)	7 (-)	3,454 (19.3)	452 (2.5)	513 (2.9)	2,764 (15.5)	4,347 (24.3)	516 (2.9)	32 (0.2)	21 (0.1)	58 (0.3)	106 (0.6)	287 (1.6)	1,970 (11.0)	1,021 (5.7)		20 (0.1)	903 (5.1)
1,737 (3.8)	571 (1.3)	687 (1.5)	19,814 (43.4)	750 (1.6)	1,313 (2.9)	1				607 (1.3)	1,386 (3.0)	6,622 (14.5)	1		3 (2-5)	1,063 (2.3)	1,250 (2.7)	4,777 (10.5)	36 (0.1)	1,201 (2.6)	21,335 (46.7)	134 (0.3)	3,561 (7.8)	789 (1.7)	4,004 (8.8)	47 (0.1)	16 (-)	350 (0.8)	292 (0.6)	599 (1.3)	5,749 (12.6)	348 (0.8)		17 (-)	1,199 (2.6)

6,097 (23.5) 8,708 (18.2) 4,546 (20.5) 4,182 (16.1) 4,043 (8.5) 3,208 (14.5) 2,659 (10.2) 1,669 (3.5) 2,001 (9.0)	44,305 (23.5) 6,097 (23.5) 8,708 (18.2) 4,546 (20.5) 22,571 (12.0) 4,182 (16.1) 4,043 (8.5) 3,208 (14.5)	44,305 (23.5) 6,097 (23.5) 8,708 (18.2) 4,546 (20.5)		1 61.728 (32.8) 5.848 (22.5) 17.589 (36.9) 5.363 (24.2) 6.592 (0 38,512 (20.5) 5,138 (19.8) 14,801 (31.0) 4,648 (21.0) 6,503 (discharge, median (IQR)	ns 1 (1-2) 2 (1-3) 1 (0-2) 2 (1-3)	10+ 14,781 (7.9) 19 (0.1) 82 (0.2) 4,055 (18.3) 10,625	9 6,353 (3.6) 76 (0.3) 149 (0.3) 2,072 (9.4) 4,051 (8 7,997 (4.3) 289 (1.1) 342 (0.7) 2,751 (12.4) 4,593 (7 9,785 (5.2) 916 (3.5) 846 (1.8) 3,396 (15.3) 4,522 (6 11,781 (6.3) 2,375 (9.1) 1,782 (3.7) 3,760 (17.0) 3,394 (5 14,643 (7.8) 4,476 (17.2) 3,428 (7.2) 3,491 (15.8) 1,586	4 18,599 (9.9) 5,892 (22.7) 5,852 (12.3) 2,095 (9.5) 153 (3 26,461 (14.1) 5,712 (22.0) 8,950 (18.8) 527 (2.4) 0 (0 (-)	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	30 days post discharge, median (IQR)	ensed 3 (2-6) 4 (3-5) 2 (1-4) 7 (5-9)	Home, no support services 90,114 (47.8) 15,798 (60.8) 24,985 (52.3) 4,542 (20.5) 9,016 (Home with support services 72,943 (38.7) 8,048 (31.0) 17,804 (37.3) 9,599 (43.3) 12,648	Long term or continuing care 25,297 (13.4) 2,149 (8.3) 4,948 (10.4) 8,006 (36.2) 7,260 (Discharge disposition			$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Medical Oncology 3,755 (2.0) - 1,188 (2.5) 353 (1.6) -	Otolaryngology 1,603 (0.9)
	1 (9.0) 2,582 (8.9)	3,814 (13.2)		6,592 (22.8)	8 (21.0) 6,503 (22.5)		(1-3) 2 $(1-3)$	i (18.3) 10,625 (36.7)	2 (9.4) 4,051 (14.0)	(12.4) 4,593 (15.9)) (17.0) 3,394 (11.7)	(15.8) 1,586 (5.5)	5 (9.5) 153 (0.5)	(2.4) 0 (-)	(-) 0 (-)	(-) 0 (-)		(5-9) 9 (7-11)	2 (20.5) 9,016 (31.2)) (43.3) 12,648 (43.7)	5 (36.2) 7,260 (25.1)			(1.9) 2.1 (1.7)	8 (4.8) 833 (2.9)	(1.6)	1
								,625 (36.7)	051 (14.0)											1							- 5	- 3
	363 (2.0)	1,247 (7.0) 6,	4,840 (27.1) 14	8,969 (50.2) 17	2,359 (13.2) 5,		1 (1-2)	0 (-)	0 (-)	2 (-)	22 (0.1)	82 (0.5)	297 (1.7)	941 (5.3)	2,235 (12.5) 9,		7,912 (44.3) 14			1,912 (66.7) 23	5,623 (31.5) 19	332 (1.9)		,		449 (2.5)		389 (2.2)
	1,883 (4.1)	6,077 (13.3)	14,772 (32.3)	17,367 (38.0)	5,063 (11.1)		2 (1-2)	0 (-)	5 (-)	20 (-)	83 (0.2)	387 (0.9)	1,365 (3.0)	3,666 (8.0)	9,037 (19.8)	16,208 (35.5)	14,913 (32.6)		2 (1-3)	23,861 (52.2)	19,331 (42.1)	2,602 (5.7)		,	1.0 (1.8)	1,062 (2.3)	1,344 (2.9)	471 (1.0)

Table 2. Prevalence of dispensed medication classes and most common ingredients in class

Dispensed Medication Classes	(%¹)	N new	Most common medications in the class overall $(\%^2)$
A02 Drugs for Acid Related Disorders	45,252 (24.0)	15,032 (8.0)	pantoprazole (64%), rabeprazole (13%), lansoprazole (16%)
A03 Drugs for Functional Gastrointestinal Disorders	3,869 (2.1)	1,457 (0.8)	domperidone (83%)
A06 Drugs for Constipation	31,048 (16.5)	20,737 (11.0)	docusate sodium (48%), lactulose (46%)
A07 Antidiarrheals, Intestinal Anti-	2,995 (1.6)	1,759 (0.9)	Ioneramide (43%) mesalazine (19%) nystatin (23%)
inflammatory/Anti-infective Agents			Toperannue (+5 %), mesatazine (15 %), nystatin (25 %)
A10 Drugs Used in Diabetes	23,337 (12.4)	5,774 (3.1)	gliclazide (16%), metformin (42%), sitagliptin (13%)
B01 Antithrombotic Agents	56,203 (29.8)	37,591 (20.0)	warfarin (30%), clopidogrel (29%), rivaroxaban (17%)
B03 Antianemic Preparations	2,788 (1.5)	815(0.4)	folic acid (93%)
C01 Cardiac Therapy	18,874 (10.0)	10,655 (5.7)	Nitroglycerin, oral and patch (32%), digoxin (48%), amiodarone (12%)
C02 Antihypertensives	2,893 (1.5)	1,230(0.7)	hydralazine (55%), doxazosin (26%), clonidine (12%)
C03 Diuretics	36,355 (19.3)	11,802 (6.3)	furosemide (78%), hydrochlorothiazide (8%)
C07 Beta Blocking Agents	41,797 (22.2)	14,722 (7.8)	metoprolol (49%), bisoprolol (36%)
C08 Calcium Channel Blockers	29,850 (15.9)	9,258 (4.9)	amlodipine (75%), diltiazem (18%)
C09 Agents Acting on Renin-Angiotensin System	40,975 (21.8)	11,487 (6.1)	ramipril (32%), perindopril (28%), candesartan (7%)
C10 Cholesterol Lowering Agents	47,317 (25.1)	9,882 (5.3)	atorvastatin (53%), rosuvastatin (32%)
D01 Antifungals for Dermatological Use	3,425 (1.8)	1,989 (1.1)	clotrimazole, topical (83%)
D07 Corticosteroids, Dermatological Preparations	2,234 (1.2)	736 (0.4)	Betamethasone, topical (63%), mometasone, topical (11%)
G04 Urologicals	16,102 (8.6)	4,020 (2.1)	tamsulosin (41%), dutasteride (13%), finasteride (11%)
H02 Corticosteroids for Systemic Use	13,729 (7.3)	6,211 (3.3)	prednisone (84%), fludrocortisone (7%), dexamethasone (6%)
H03 Thyroid Therapy	17,747 (9.4)	1,022(0.5)	levothyroxine (99%)
J01 Antibacterials for Systemic Use	43,107 (22.9)	34,355 (18.2)	ciprofloxacin (15%), cefalexin (14%), amoxicillin & beta-lactamase inhibitor (14%), cefuroxime (11%)
J05 Antivirals for Systemic Use	1,808(1.0)	1,319(0.7)	oseltamivir (82%), valaciclovir (5%), valaciclovir (5%)
M01 Anti-inflammatory Products	5,580 (3.0)	3,185(1.7)	celecoxib (38%), meloxicam (21%), naproxen (16%), ibuprofen (14%)
M04 Antigout Preparations	5,057 (2.7)	501(0.3)	allopurinol (99%)
M05 Drugs for Treatment of Bone Diseases	7,867 (4.2)	1,248(0.7)	risedronic acid (74%), alendronic acid & cholecalciferol (12%)
N02 Analgesics	75,579 (40.1)	53,572 (28.4)	hydromorphone (50%), oxycodone (29%), codeine & paracetamol (8%)
N03 Antiepileptics	17,386 (9.2)	4,839 (2.6)	gabapentin (28%), pregabalin (22%), phenytoin (16%)
N04 Anti-Parkinson Drugs	3,886 (2.1)	411 (0.2)	levodopa & decarboxylase inhibitor (69%), pramipexole (10%)

N05 Psycholeptics	18,879 (10.0)	6,559(3.5)	quetiapine (31%), risperidone (19%), lorazepam (15%)
N06 Psychoanaleptics	32,555 (17.3)	6,288 (3.3)	trazodone (25%), escitalopram (14%), mirtazapine (11%), donepezil (11%)
P01 Antiprotozoals	4,513 (2.4)	3,723 (2.0)	metronidazole (80%), hydroxychloroquine (20%)
R03 Drugs for Obstructive Airway Diseases	24,520 (13.0) 11,549 (6.1)		salbutamol (41%), tiotropium bromide (16%), salmeterol & fluticasone (13%)
S01 Ophthalmologicals	5,894 (3.1)	1,272(0.7)	latanoprost (21%), timolol, combinations (11%)
1% is of all nationts			

²% is of all *medications* dispensed in that class

Table 3. Association Between Patient Characteristics and Risk of Adverse Drug Events in 30-days Following Discharge

Patient Characteristics	Crude Risk of ADE (%)	Adjusted OR ADE (%)	Lower 95% CI for adjusted OR	Upper 95% CI for adjusted OR
Demographics				
Age				
66-75	5.7		Reference	
76-85	7.3	1.13	1.09	1.19
85+	8.0	1.19	1.13	1.26
Sex				
Male	6.7	1.00	Reference	1.06
Female Health services 1-year prior to admission	6.8	1.02	0.99	1.06
Hospitalizations				
0	6.2		Reference	
1	7.9	1.00	0.94	1.06
2	10.3	1.08	0.99	1.18
3	12.7	1.22	1.07	1.39
4+	14.1	1.24	1.07	1.44
Emergency department visits				
0	3.0		Reference	
1	5.7	1.19	1.07	1.32
2	6.5	1.29	1.16	1.44
3	7.9	1.49	1.33	1.67
4	8.1	1.45	1.28	1.63
5	8.4	1.44	1.26	1.64
6+	10.6	1.69	1.50	1.90
Distinct medications dispensed				
0	4.7		Reference	
1-3	4.6	1.02	0.87	1.21
4-6	5.1	1.08	0.92	1.26
7-9	6.0	1.15	0.98	1.35
10-12	7.0	1.26	1.07	1.48
13-15	8.1	1.37	1.16	1.61
16+	10.2	1.55	1.31	1.83
Chronic Conditions				
Acute myocardial infarction	8.7	1.03	0.95	1.12
Arrythmia	8.6	1.10	1.05	1.16
Heart failure	11.6	1.21	1.15	1.27
Coronary artery syndrome	7.4	0.96	0.91	1.01
Hypertension	6.7	1.03	0.99	1.07

Stroke	7.2	0.92	0.94	0.99
Cancer	6.9	0.96	0.92	1.00
Diabetes	7.6	0.97	0.92	1.01
Chronic obstructive pulmonary disease	7.9	0.99	0.94	1.05
Asthma	7.5	1.01	0.93	1.09
Dementia	7.8	1.01	0.95	1.07
Mental health disorders	7.2	0.99	0.92	1.05
Mood and anxiety disorders	7.4	1.02	0.98	1.08
Osteoporosis	6.4	0.98	0.89	1.08
Osteoarthritis	5.3	0.99	0.94	1.05
Arthritis	6.2	0.97	0.92	1.02
Rheumatoid arthritis	6.7	1.00	0.90	1.12
Renal disease	11.6	1.42	1.34	1.50
Liver disease	12.6	1.54	1.34	1.77
Index admission characteristics				
Institution admitted from				
Community, no home care	6.5		Reference	
Community, home care	7.9	0.91	0.70	1.18
Long term care	8.3	1.09	1.03	1.17
Ambulatory care	7.7	1.09	1.01	1.19
Unclassified	7.7	1.13	0.76	1.70
Acuity				
Not admitted from ED	4.2		Reference	
Admitted from the ED	7.7	1.23	1.14	1.33
Main Patient Service	0.1		D (
General Medicine	8.1	0.01	Reference	0.07
General Practice	6.5	0.81	0.68	0.97
Cardiology	8.2	0.95	0.88	1.02
Gastro-Enterology	8.6	1.02	0.91	1.15
Nephrology	10.9	0.93	0.78	1.11
Neurology	6.5	0.91	0.77	1.07
Respirology	7.7	1.02	0.92	1.13
General Surgery	4.2	0.68	0.62	0.74
Cardio Surgery	6.9	1.06	0.94	1.20
Neurosurgery	5.2	0.98	0.78	1.23
Orthopaedic Surgery	3.6	0.84	0.75	0.94
Thoracic Surgery	6.0	0.89	0.69	1.15
Urology	4.2	0.60	0.53	0.68
Otolaryngology	3.9	0.64	0.49	0.83
Medical Oncology	8.7	0.95	0.83	1.09
Other	6.7	0.99	0.88	1.11
Reason for Admission*				
Circulatory	8.4		Reference	
Infection	6.8	1.00	0.90	1.11
Neoplasm	8.4	1.08	0.97	1.20
Endocrine	7.5	0.95	0.85	1.07

7.5	0.87	0.77	0.99
5.8	0.78	0.67	0.91
4.3	0.65	0.29	1.48
5.4	0.81	0.53	1.24
7.2	0.76	0.70	0.83
6.9	0.98	0.90	1.07
8.3	0.91	0.77	1.08
3.8	0.86	0.77	0.96
7.5	1.04	0.95	1.15
3.8	0.68	0.25	1.84
4.5	0.64	0.58	0.71
4.9	0.65	0.56	0.75
7.2	0.93	0.86	1.01
-	1.01	1.01	1.02
-	1.05	1.04	1.06
6.7		Reference	
6.7	1.14	1.08	1.21
6.2	1.16	1.09	1.22
6.8	1.23	1.15	1.32
7.5	1.31	1.20	1.42
8.4	1.39	1.27	1.52
7.0	0.97	0.92	1.03
7.7	1.12	1.08	1.17
6.6	0.82	0.77	0.87
8.9	0.98	0.94	1.03
()	1 01	0.04	1 00
6.0 4.6	1.01	0.94 0.97	1.08
	5.8 4.3 5.4 7.2 6.9 8.3 3.8 7.5 3.8 4.5 4.9 7.2	5.8 0.78 4.3 0.65 5.4 0.81 7.2 0.76 6.9 0.98 8.3 0.91 3.8 0.86 7.5 1.04 3.8 0.68 4.5 0.64 4.9 0.65 7.2 0.93 - 1.01 - 1.05 6.7 6.7 1.14 6.8 1.23 7.5 1.31 8.4 1.39 7.0 0.97 7.7 1.12 6.6 0.82 8.9 0.98	5.8 0.78 0.67 4.3 0.65 0.29 5.4 0.81 0.53 7.2 0.76 0.70 6.9 0.98 0.90 8.3 0.91 0.77 3.8 0.86 0.77 7.5 1.04 0.95 3.8 0.68 0.25 4.5 0.64 0.58 4.9 0.65 0.56 7.2 0.93 0.86 - 1.01 1.01 - 1.05 1.04 6.7 1.14 1.08 6.2 1.16 1.09 6.8 1.23 1.15 7.5 1.31 1.20 8.4 1.39 1.27 7.0 0.97 0.92 7.7 1.12 1.08 6.6 0.82 0.77 8.9 0.98 0.94

¹Reference is all other clusters (e.g., cardiovascular vs not)

Table A1. List of medication classes excluded from analysis

3 Digit ATC code	Class Name
A01	STOMATOLOGICAL PREPARATIONS
A05	BILE AND LIVER THERAPY
A09	DIGESTIVES, INCL. ENZYMES
A11	VITAMINS
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
B02	ANTIHEMORRHAGICS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
C04	PERIPHERAL VASODILATORS
C05	VASOPROTECTIVES
D03	PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS
D05	ANTIPSORIATICS
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D10	ANTI-ACNE PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
G02	OTHER GYNECOLOGICALS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H04	PANCREATIC HORMONES
H05	CALCIUM HOMEOSTASIS
J02	ANTIMYCOTICS FOR SYSTEMIC USE
J04	ANTIMYCOBACTERIALS
J07	VACCINES
L01	ANTINEOPLASTIC AGENTS
L02	ENDOCRINE THERAPY
L03	IMMUNOSTIMULANTS
L04	IMMUNOSUPPRESSANTS
M03	MUSCLE RELAXANTS
N07	OTHER NERVOUS SYSTEM DRUGS
P02	ANTHELMINTICS
P03	ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS
R01	NASAL PREPARATIONS
R05	COUGH AND COLD PREPARATIONS
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R07	OTHER RESPIRATORY SYSTEM PRODUCTS
S02	OTOLOGICALS

S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V07	ALL OTHER NON-THERAPEUTIC PRODUCTS

Table A2. IC9 and ICD 10 codes used to define pre-admission chronic conditions

Condition	ICD 9	ICD 10
Acute Myocardial Infarction (AMI)	410	121, 122
Osteo- and other Arthritis:		
(A) Osteoarthritis	715	M15-M19
(B) Other Arthritis (includes Synovitis, Fibrositis, Connective tissue disorders, Ankylosing spondylitis, Gout Traumatic arthritis, pyogenic arthritis, Joint derangement, Dupuytren's contracture, Other MSK disorders)	727, 729, 710, 720, 274, 716, 711, 718, 728, 739	M00-M03, M07, M10, M11-M14, M20-M25, M30-M36, M65-M79
Arthritis - Rheumatoid arthritis	714	M05-M06
Asthma	493	J45
(all) Cancers	140-239	C00-C26, C30-C44, C45-C97
Cardiac Arrhythmia	427 (OHIP) / 427.3 (DAD)	I48.0, I48.1
Congestive Heart Failure	428	I500, I501, I509
Chronic Obstructive Pulmonary Disease	491, 492, 496	J41, J43, J44
Coronary syndrome (excluding AMI)	411-414	120, 122-125
Dementia	290, 331 (OHIP) / 046.1, 290.0, 290.1, 290.2, 290.3, 290.4, 294, 331.0, 331.1, 331.5, F331.82 (DAD)	F00, F01, F02, F03, G30
Diabetes	250	E08 - E13
Hypertension	401, 402, 403, 404, 405	110, 111, 112, 113, 115
(Other) Mental Illnesses	291, 292, 295, 297, 298, 299, 301, 302, 303, 304, 305, 306, 307, 313, 314, 315, 319	F04, F050, F058, F059, F060, F061, F062, F063, F064, F07, F08, F10, F11, F12, F13, F14, F15, F16, F17, F18, F19, F20, F21, F22, F23, F24, F25, F26, F27, F28, F29, F340, F35, F36, F37, F430, F439, F453, F454, F458, F46, F47, F49, F50, F51, F52, F531, F538, F539, F54, F55, F56, F57, F58, F59, F60, F61, F62, F63, F64, F65, F66, F67, F681, F688, F69, F70, F71, F72, F73, F74, F75, F76, F77, F78, F79, F80, F81, F82, F83, F84, F85, F86, F87, F88, F89, F90, F91, F92, F931, F932, F933, F938, F939, F94, F95, F96, F97, F98
Mood, anxiety, depression and other nonpsychotic disorders	296, 300, 309, 311	F30, F31, F32, F33, F34 (excl. F34.0), F38, F39, F40, F41, F42, F43.1, F43.2, F43.8, F44, F45.0, F45.1, F45.2, F48, F53.0, F68.0, F93.0, F99
Osteoporosis	733	M81, M82
Renal failure	403, 404, 584, 585, 586, v451	N17, N18, N19, T82.4, Z49.2, Z99.2

Stroke (excluding transient ischemic attack)

430, 431, 432, 434, 436

I60-I64

Table A3. ICD 10 codes used to define adverse drug events (ADEs)

Code	Meaning
D52.1	Drug-induced folate deficiency anaemia
D59.0	Drug-induced autoimmune haemolytic anaemia
D59.2	Drug-induced nonautoimmune haemolytic anaemia
D61.1	Drug-induced aplastic anaemia due to chemotherapy
D68.3	Hemorrhagic disorder due to circulating anticoagulants
E06.4	Drug-induced thyroiditis
E16.0	Drug-induced hypoglycaemia without coma
E23.1	Drug-induced hypopituitarism
E24.2	Drug-induced Cushing's syndrome
E27.3	Drug-induced adrenocortical insufficiency
E66.1	Drug-induced obesity
G21.0	Malignant neuroleptic syndrome
G21.1	Other drug-induced secondary parkinsonism
G24.0	Drug-induced dystonia
G25.1	Drug-induced tremor
G25.4	Drug-induced chorea
G25.6	Drug-induced tics and other tics of organic origin
G44.4	Drug-induced headache, not elsewhere classified
G62.0	Drug-induced polyneuropathy
G72.0	Drug-induced myopathy
H26.3	Drug-induced cataract
H40.6	Glaucoma secondary to drugs
195.2	Hypotension due to drugs
J70.2	Acute drug-induced interstitial lung disorders
J70.3	Chronic drug-induced interstitial lung disorders
J70.4	Drug-induced interstitial lung disorders, unspecified
K85.3	Drug-induced pancreatitis
L10.5	Drug-induced pemphigus
L43.2	Lichenoid drug reaction
L56.0	Drug phototoxic response
L56.1	Drug photoallergic response
L64.0	Drug-induced androgenic alopecia
M10.2	Drug-induced gout
M32.0	Drug-induced systemic lupus erythematosus
M80.4	Drug-induced osteoporosis with pathological fracture
M81.4	Drug-induced osteoporosis without pathological fracture
M83.5	Other drug-induced osteomalacia in adults
M87.1	Osteonecrosis due to drugs
N14.0	Analgesic nephropathy
O74.4	Toxic reaction to local anaesthesia during labour and delivery
P04.0	Fetus and newborn affected by maternal anaesthesia and analgesia in pregnancy, labour and delivery
P04.1	Fetus and newborn affected by other maternal medication
P96.2	Withdrawal symptoms from therapeutic use of drugs in newborn
Q86.1	Fetal hydantoin syndrome
Q00.1	1 ctar nyuamom synurome

Q86.2	Dysmorphism due to warfarin
R50.2	Drug-induced fever
T88.3	Malignant hyperthermia due to anaesthesia
Y40-Y59	Adverse Drug reactions
1.0.10	Drugs, medicaments, and biological substances causing adverse effects in therapeutic use -
Y40	systemic antibiotic
	Drugs, medicaments, and biological substances causing adverse effects in therapeutic use - other
Y41	systemic anti-infectives and antiparasitics
	Drugs, medicaments, and biological substances causing adverse effects in therapeutic use -
Y42	Hormones and their synthetic substitutes and antagonists, not elsewhere classified
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
3/40.7	Hormones and their synthetic substitutes and antagonists, not elsewhere classified, Androgens and
Y42.7	anabolic congener Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y43	Primarily systemic agents
173	Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Agents
Y44	primarily affecting blood constituents
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Agents
	primarily affecting blood constituents, Iron preparations and other anti-hypochromic-anaemia
Y44.0	preparations
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Agents
Y44.2	primarily affecting blood constituents, Anticoagulants
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y45	Analgesics, antipyretics and anti-inflammatory drugs
V/15 5	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y45.5	Analgesics, antipyretics and anti-inflammatory drugs, 4-Aminophenol derivatives Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y46	Antiepileptics and antiparkinsonism drugs
140	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y47	Sedatives, hypnotics and antianxiety drugs
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y47.1	Sedatives, hypnotics and antianxiety drugs, Benzodiazepines
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y48	Anaesthetics and therapeutic gases
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y48.1	Anaesthetics and therapeutic gases, Parenteral anaesthetics
V40 2	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y48.2	Anaesthetics and therapeutic gases, Other and unspecified general anaesthetics Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y48.3	Anaesthetics and therapeutic gases, Local anaesthetics
1 40.5	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y48.4	Anaesthetics and therapeutic gases, Anaesthetic, unspecified
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -
Y49	Psychotropic drugs, not elsewhere classified
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Central
Y50	nervous system stimulants, not elsewhere classified
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Drugs
Y51	primarily affecting the autonomic nervous system
V/50	Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Agents
Y52	primarily affecting the cardiovascular system Drugs medicements and hiological substances causing adverse effects in therapeutic use. Agents
Y53	Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Agents primarily affecting the gastrointestinal system
1 00	Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Agents
Y54	primarily affecting water-balance and mineral and uric acid metabolism
101	Francisco and control and also deta inemporium

Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Agents Y55 primarily acting on smooth and skeletal muscles and the respiratory system Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Agents primarily acting on smooth and skeletal muscles and the respiratory system, Skeletal muscle Y55.1 relaxants [neuromuscular blocking agents] Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Topical agents primarily affecting skin and mucous membrane and ophthalmological, Y56 otorhinolaryngological and dental drugs Drugs, medicaments and biological substances causing adverse effects in therapeutic use -Other Y57 and unspecified drugs and medicaments Drugs, medicaments and biological substances causing adverse effects in therapeutic use -Other Y57.5 and unspecified drugs and medicaments, X-ray contrast media Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Bacterial Y58 vaccines Drugs, medicaments and biological substances causing adverse effects in therapeutic use - Other Y59 and unspecified vaccines and biological substances Sequelae of adverse effects caused by drugs, medicaments and biological substances in therapeutic Y88.0 D64.2 Secondary sideroblastic anaemia due to drugs and toxins E03.2 Hypothyroidism due to medicaments and other exogenous substances F11 Mental and behavioural disorders due to use of opioids F11.0 Mental and behavioural disorders due to use of opioids: Acute intoxication F11.1 Mental and behavioural disorders due to use of opioids: Harmful use F11.2 Mental and behavioural disorders due to use of opioids: Dependence syndrome F11.3 Mental and behavioural disorders due to use of opioids: Withdrawal state F11.4 Mental and behavioural disorders due to use of opioids: Withdrawal state with delirium Mental and behavioural disorders due to use of opioids: Psychotic disorder F11.5 F11.6 Mental and behavioural disorders due to use of opioids: Amnesic syndrome F11.7 Mental and behavioural disorders due to use of opioids: Residual and late-onset psychotic disorder Mental and behavioural disorders due to use of opioids: Other mental and behavioural disorders F11.8 Mental and behavioural disorders due to use of opioids: Unspecified mental and behavioural F11.9 disorder F13 Mental and behavioural disorders due to use of sedatives or hypnotics F13.0 Mental and behavioural disorders due to use of sedatives or hypnotics: Acute intoxication F13.1 Mental and behavioural disorders due to use of sedatives or hypnotics: Harmful use F13.2 Mental and behavioural disorders due to use of sedatives or hypnotics: Dependence syndrome F13.3 Mental and behavioural disorders due to use of sedatives or hypnotics: Withdrawal state Mental and behavioural disorders due to use of sedatives or hypnotics: Withdrawal state with F13.4 F13.5 Mental and behavioural disorders due to use of sedatives or hypnotics: Psychotic disorder F13.6 Mental and behavioural disorders due to use of sedatives or hypnotics: Amnesic syndrome Mental and behavioural disorders due to use of sedatives or hypnotics: Residual and late-onset F13.7 psychiatric disorder Mental and behavioural disorders due to use of sedatives or hypnotics: Other mental and F13.8 behavioural disorders Mental and behavioural disorders due to use of sedatives or hypnotics: Unspecified mental and F13.9 behavioural disorder Mental and behavioural disorders due to use of other stimulants, including caffeine: Acute F15.0 intoxication F15.1 Mental and behavioural disorders due to use of other stimulants, including caffeine: Harmful use Mental and behavioural disorders due to use of other stimulants, including caffeine: Dependence F15.2 syndrome

Mental and behavioural disorders due to use of other stimulants, including caffeine: Withdrawal F15.3 Mental and behavioural disorders due to use of other stimulants, including caffeine: Withdrawal F15.4 state with delirium Mental and behavioural disorders due to use of other stimulants, including caffeine: Psychotic F15.5 Mental and behavioural disorders due to use of other stimulants, including caffeine: Amnesic F15.6 syndrome Mental and behavioural disorders due to use of other stimulants, including caffeine: Residual and F15.7 late-onset psychotic disorder Mental and behavioural disorders due to use of other stimulants, including caffeine: Other mental F15.8 and behavioural disorders Mental and behavioural disorders due to use of other stimulants, including caffeine: Unspecified F15.9 mental and behavioural disorder Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.0 substances: Acute intoxication Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.1 substances: Harmful use Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.2 substances: Dependence syndrome Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.3 substances: Withdrawal state Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.4 substances: Withdrawal state with delirium Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.5 substances: Psychotic disorder Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.6 substances: Amnesic syndrome Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.7 substances: Residual and late-onset psychotic disorder Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.8 substances: Other mental and behavioural disorders Mental and behavioural disorders due to multiple drug use and use of other psychoactive F19.9 substances: Unspecified mental and behavioural disorder G21.2 Secondary parkinsonism due to other external agents I42.7 Cardiomyopathy due to drugs and other external agents L23.3 Allergic contact dermatitis due to drugs in contact with skin L24.4 Irritant contact dermatitis due to drugs in contact with skin L25.1 Unspecified contact dermatitis due to drugs in contact with skin L27 Dermatitis due to substances taken internally L27.0 Generalized skin eruption due to drugs and medicaments Localized skin eruption due to drugs and medicaments L27.1 L27.8 Dermatitis due to other substances taken internally L27.9 Dermatitis due to unspecified substance taken internally M34.2 Systemic sclerosis induced by drugs and chemicals N14.1 Nephropathy induced by other drugs, medicaments and biological substances N14.2 Nephropathy induced by unspecified drug, medicament or biological substance N14.3 Nephropathy induced by heavy metals N14.4 Toxic nephropathy, not elsewhere classified O35.5 Maternal care for (suspected) damage to fetus by drugs P04.4 Fetus and newborn affected by maternal use of drugs of addiction P58.4 Neonatal jaundice due to drugs or toxins transmitted from mother or given to newborn P93 Reactions and intoxications due to drugs administered to fetus and newborn

P96.1	Neonatal withdrawal symptoms from maternal use of drugs of addiction
T78	Adverse effects, not elsewhere classified
T78.2	Anaphylactic shock, unspecified
T78.3	Angioneurotic oedema
T78.4	Allergy, unspecified
T78.8	Other adverse effects, not elsewhere classified
T78.9	Adverse effect, unspecified
T80.1	Vascular complications following infusion, transfusion and therapeutic injection
T80.2	Infections following infusion, transfusion and therapeutic injection
T80.3	ABO incompatibility reaction
T80.4	Rh incompatibility reaction
100	Complications following infusion, transfusion and therapeutic injection: anaphylactic shock due to
T80.5	serum
T80.6	Complications following infusion, transfusion and therapeutic injection: other serum reactions
T80.8	Other complications following infusion, transfusion and therapeutic injection
T80.9	Unspecified complication following infusion, transfusion and therapeutic injection
T88.6	Anaphylactic shock due to adverse effect of correct drug or medicament properly administered
T88.7	Unspecified adverse event of drug or medicament
	Drugs, medicaments and biological substances causing adverse effects in therapeutic use -Other
Y57.9	and unspecified drugs and medicaments, Drug or medicament, unspecified
Y59.9	Vaccine or biological substance, unspecified
Z03.6	Observation for suspected toxic effect from ingested substance
	Poisoning by drugs, medicaments and biological substances: "premature, excessive, inappropriate
T36-T50	or wrong medication, formulation or route"9 overdose of these substances (accidental or not) - wrong substance given or taken in error
T36	Poisoning by systemic antibiotics
T36.0	Penicillins
T36.1	Cefalosporins and other beta-lactam antibiotics
T36.2	Chloramphenicol group
T36.3	Macrolides
T36.4	Tetracyclines
T36.5	Aminoglycosides
T36.6	Rifamycins
T36.7	Antifungal antibiotics, systemically used
T36.8	Other systemic antibiotics
T36.9	Systemic antibiotic, unspecified
T37	Poisoning by other systemic anti-infectives and anti-parasitics
T37.0	Sulfonamides
T37.0	Antimycobacterial drugs
T37.1	Antimalarials and drugs acting on other blood protozoa
T37.3	Other antiprotozoal drugs
T37.4	Anthelminthics
T37.5	Antiviral drugs
T37.8	Other specified systemic anti-infectives and antiparasitics
T37.9	Systemic anti-infective and antiparasitic, unspecified
T38	Poisoning by hormones and their synthetic substitutes and antagonists, not elsewhere classified
T38.0	Glucocorticoids and synthetic analogues
T38.1	Thyroid hormones and substitutes
T38.2	Antithyroid drugs
T38.3	Insulin and oral hypoglycaemic [antidiabetic] drugs
150.5	mount and oral hypogryouchine fantataconed arags

T38.4	Oral contraceptives
T38.5	Other estrogens and progestogens
T38.6	Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified
T38.7	Androgens and anabolic congeners
T38.8	Other and unspecified hormones and their synthetic substitutes
T38.9	Other and unspecified hormone antagonists
T39	Poisoning by nonopioid analgesics, antipyretics and antirheumatics
T39.0	Salicylates
T39.1	4-Aminophenol derivatives
T39.2	Pyrazolone derivatives
T39.3	Other nonsteroidal anti-inflammatory drugs [NSAID]
T39.4	Antirheumatics, not elsewhere classified
T39.8	Other nonopioid analgesics and antipyretics, not elsewhere classified
T39.9	Nonopioid analgesic, antipyretic and antirheumatic, unspecified
T40	Poisoning by narcotics and psychodysleptics
T40.0	Opium
T40.1	Heroin
T40.2	Poisoning by other opioids (includes morphine and codeine)
T40.3	Poisoning by Methadone
T40.4	Poisoning by other synthetic narcotics (buprenorphine, pethidine, destropropoxyphene etc.)
T40.5	Cocaine
T40.6	Poisoning by other and unspecified narcotics
T40.7	Cannabis (derivatives)
T40.8	Lysergide [LSD]
T40.9	Other and unspecified psychodysleptics [hallucinogens]
T41	Poisoning by anaesthetics and therpeutic gases
T41.0	Inhaled anaesthetics
T41.1	Intravenous anaesthetics
T41.2	Other and unspecified general anaesthetics
T41.3	Local anaesthetics
T41.4	Anaesthetic, unspecified
T41.5	Therapeutic gases
T42	Poisoning by antiepileptic, sedative-hypnotic and antiparkinsonism drugs
T42.0	Hydantoin derivatives
	Iminostilbenes
T42.1	
T42.2	Succinimides and oxazolidinediones Barbiturates
T42.3	
T42.4	Poisoning by benzodiazepines
T42.5	Mixed antiepileptics, not elsewhere classified
T42.6	Other antiepileptic and sedative-hypnotic drugs
T42.7	Antiepileptic and sedative-hypnotic drugs, unspecified
T42.8	Antiparkinsonism drugs and other central muscle-tone depressants
T43	Poisoning by psychotropic drugs, not elsewhere classified
T43.0	Poisoning by tricyclic and tetracyclic antidepressants
T43.1	Monoamine-oxidase-inhibitor antidepressants
T43.2	Poisoning by other and unspecified antidepressants
T43.3	Phenothiazine antipsychotics and neuroleptics
T43.4	Butyrophenone and thioxanthene neuroleptics
T43.5	Other and unspecified antipsychotics and neuroleptics

T43.6	Poisoning by psychostimulants with abuse potential
T43.8	Other psychotropic drugs, not elsewhere classified
T43.9	Psychotropic drug, unspecified
T44	Poisoning by drugs primarily affecting the autonomic nervous system
T44.0	Anticholinesterase agents
T44.1	Other parasympathomimetics [cholinergics]
T44.2	Ganglionic blocking drugs, not elsewhere classified
	Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, not elsewhere
T44.3	classified
T44.4	Predominantly alpha-adrenoreceptor agonists, not elsewhere classified
T44.5	Predominantly beta-adrenoreceptor agonists, not elsewhere classified
T44.6	Alpha-adrenoreceptor antagonists, not elsewhere classified
T44.7	Beta-adrenoreceptor antagonists, not elsewhere classified
T44.8	Centrally acting and adrenergic-neuron-blocking agents, not elsewhere classified
T44.9	Other and unspecified drugs primarily affecting the autonomic nervous system
T45	Poisoning by primarily ststemic and haematological agents, not elsewhere classified
T45.0	Antiallergic and antiemetic drugs
T45.1	Antineoplastic and immunosuppressive drugs
T45.2	Vitamins, not elsewhere classified
T45.3	Enzymes, not elsewhere classified
T45.4	Iron and its compounds
T45.5	Anticoagulants
T45.6	Fibrinolysis-affecting drugs
T45.7	Anticoagulant antagonists, vitamin K and other coagulants
T45.8	Other primarily systemic and haematological agents
T45.9	Primarily systemic and haematological agent, unspecified
T46	Poisoning by agents primarily affecting the cardiovascular system
T46.0	Cardiac-stimulant glycosides and drugs of similar action
T46.1	Calcium-channel blockers
T46.2	Other antidysrhythmic drugs, not elsewhere classified
T46.3	Coronary vasodilators, not elsewhere classified
T46.4	Angiotensin-converting-enzyme inhibitors
T46.5	Other antihypertensive drugs, not elsewhere classified
T46.6	Antihyperlipidaemic and antiarteriosclerotic drugs
T46.7	Peripheral vasodilators
T46.8	Antivaricose drugs, including sclerosing agents
T46.9	Other and unspecified agents primarily affecting the cardiovascular system
T47	Poisoning by agents primarily affecting the gastrointestinal system
T47.0	Histamine H 2 -receptor antagonists
T47.1	Other antacids and anti-gastric-secretion drugs
T47.2	Stimulant laxatives
T47.3	Saline and osmotic laxatives
T47.4	Other laxatives
T47.5	Digestants
T47.6	Antidiarrhoeal drugs
T47.7	Emetics Other approximation of the first in the protection of the first interestinal countries.
T47.8	Other agents primarily affecting the gastrointestinal system
T47.9	Agent primarily affecting the gastrointestinal system, unspecified
T48	Poisoning by agents primarily acting on smooth and skeletal muscles and the respiratory system
T48.0	Oxytocic drugs

T48.1	Skeletal muscle relaxants [neuromuscular blocking agents]
T48.2	Other and unspecified agents primarily acting on muscles
T48.3	Antitussives
T48.4	Expectorants
T48.5	Anti-common-cold drugs
T48.6	Antiasthmatics, not elsewhere classified
T48.7	Other and unspecified agents primarily acting on the respiratory system
T49.0	Local antifungal, anti-infective and anti-inflammatory drugs, not elsewhere classified
11,510	Poisoning by topical agents primarily affecting skin and mucous membrane and by
T49	ophthalmological, otorhinolaryngological and dental drugs
T49.1	Antipruritics
T49.2	Local astringents and local detergents
T49.3	Emollients, demulcents and protectants
T49.4	Keratolytics, keratoplastics and other hair treatment drugs and preparations
T49.5	Ophthalmological drugs and preparations
T49.6	Otorhinolaryngological drugs and preparations
T49.7	Dental drugs, topically applied
T49.8	Other topical agents
T49.9	Topical agent, unspecified
T50	Poisoning by diuretics and other unspecified drugs, medicaments and biological substances
T50.0	Mineralocorticoids and their antagonists
T50.1	Loop [high-ceiling] diuretics
T50.2	Carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics
T50.4	Drugs affecting uric acid metabolism
T50.6	Antidotes and chelating agents, not elsewhere classified
T50.7	Analeptics and opioid receptor antagonists
F55	Abuse of non-dependence-producing substances
T50.3	Electrolytic, caloric and water-balance agents
T50.5	Appetite depressants
T50.8	Diagnostic agents
T50.9	Poisoning: Other and unspecified drugs, medicaments and biological substances
T96	Sequelae of poisoning by drugs, medicaments and biological substances
V40	Accidental poisoning by and exposure to nonopioid analgesics, antipyretics, and antirheumatics
X40	including acetominophen Accidental poisoning by and exposure to antiepileptic, sedative hypnotic, antiparkinsonism,
X41	psychotropic drugs NEC
	Accidental poisoning by and exposure to narcotics and psychodysleptics (hallucinogens) NEC
	(includes diamorphine (heroin), cocaine, codeine, lysergide (LSD), morphine, pethidine, narcotic
X42	NEC, hallucinogen NEC, hydrocodone, oxycodone (oxycontin) and fentanyl, among others)
X43	Accidental poisoning by and exposure to other drugs acting on the autonomic nervous system
37.4.4	Accidental poisoning by and exposure to other and unspecified drugs, medicaments, and biological
X44	substances
X45.5	Adverse effects of therapeutic use of 4-aminophenol derivatives Poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics, undetermined
Y10	intent
A04.7	Enterocolitis due to Clostridium difficile
E15	Nondiabetic hypoglycaemic coma
H91.0	Ototoxic hearing loss
K52.1	Toxic gastroenteritis and colitis
K71.0	Toxic liver disease with cholestasis
K71.1	Toxic liver disease with hepatic necrosis
=	1

	and the state of t
K71.2	Toxic liver disease with acute hepatitis
K71.3	Toxic liver disease with chronic persistent hepatitis
K71.4	Toxic liver disease with chronic lobular hepatitis
K71.5	Toxic liver disease with chronic active hepatitis
K71.6	Toxic liver disease with hepatitis, not elsewhere classified
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver
K71.8	Toxic liver disease with other disorders of liver
K71.9	Toxic liver disease, unspecified
L51	Erythema multiforme
L51.0	Nonbullous erythema multiforme
L51.1	Bullous erythema multiforme
L51.2	Toxic epidermal necrolysis [Lyell]
L51.8	Other erythema multiforme
L51.9	Erythema multiforme, unspecified
L56.2	Photocontact dermatitis [berloque dermatitis]
N99.0	Postprocedural renal failure
O74.2	Cardiac complications of anaesthesia during labour and delivery
O74.3	Central nervous system complications of anaesthesia during labour and delivery
Y63	Failure in dosage during surgical and medical care
Y65.1	Wrong fluid in infusion
Y69	Unspecified misadventure during surgical and medical care
D62	Acute posthaemorrhagic anaemia
D69.5	Secondary thrombocytopenia
D69.6	Thrombocytopenia, unspecified
D70	Agranulocytosis
F52	Sexual dysfunction, not caused by organic disorder or disease
F52.0	Lack or loss of sexual desire
F52.1	Sexual aversion and lack of sexual enjoyment
F52.2	Failure of genital response
F52.3	Orgasmic dysfunction
F52.4	Premature ejaculation
F52.5	Nonorganic vaginismus
F52.6	Nonorganic dyspareunia
F52.7	Excessive sexual drive
F52.8	Other sexual dysfunction, not caused by organic disorder or disease
F52.9	Unspecified sexual dysfunction, not caused by organic disorder or disease
H53	Visual disturbances
H53.0	Amblyopia ex anopsia
H53.1	Subjective visual disturbances
H53.2	Diplopia
H53.3	Other disorders of binocular vision
H53.4	Visual field defects
H53.5	Colour vision deficiencies
H53.6	Night blindness
H53.8	Other visual disturbances
H53.9	Visual disturbance, unspecified
I15.8	Other secondary hypertension
I15.9	Secondary hypertension, unspecified
J45.1	Nonallergic asthma

V25 0	Costrio vicem Acute with hearnamheas
K25.0 K25.1	Gastric ulcer: Acute with haemorrhage
	Gastric ulcer: Acute with perforation
K25.2	Gastric ulcer: Acute with both haemorrhage and perforation
K25.3	Gastric ulcer: Acute without haemorrhage or perforation
K25.4	Gastric ulcer: Chronic or unspecified with haemorrhage
K25.5	Gastric ulcer: Chronic or unspecified with perforation
K25.6	Gastric ulcer: Chronic or unspecified with both haemorrhage and perforation
K25.7	Gastric ulcer: Chronic without haemorrhage or perforation
K25.9	Gastric ulcer: Unspecified as acute or chronic, without haemorrhage or perforation
K26.0	Duodenal ulcer: Acute with haemorrhage
K26.1	Duodenal ulcer: Acute with perforation
K26.2	Duodenal ulcer: Acute with both haemorrhage and perforation
K26.3	Duodenal ulcer: Acute without haemorrhage or perforation
K26.4	Duodenal ulcer: Chronic or unspecified with haemorrhage
K26.5	Duodenal ulcer: Chronic or unspecified with perforation
K26.6	Duodenal ulcer: Chronic or unspecified with both haemorrhage and perforation
K26.7	Duodenal ulcer: Chronic without haemorrhage or perforation
K26.9	Duodenal ulcer: Unspecified as acute or chronic, without haemorrhage or perforation
K27.0	Peptic ulcer, site unspecified: Acute with haemorrhage
K27.1	Peptic ulcer, site unspecified: Acute with perforation
K27.2	Peptic ulcer, site unspecified: Acute with both haemorrhage and perforation
K27.3	Peptic ulcer, site unspecified: Acute without haemorrhage or perforation
K27.4	Peptic ulcer, site unspecified: Chronic or unspecified with haemorrhage
K27.5	Peptic ulcer, site unspecified: Chronic or unspecified with perforation
K27.6	Peptic ulcer, site unspecified: Chronic or unspecified with both haemorrhage and perforation
K27.7	Peptic ulcer, site unspecified: Chronic without haemorrhage or perforation
K27.9	Peptic ulcer, site unspecified: Unspecified as acute or chronic, without haemorrhage or perforation
K28	Gastrojujenal ulcer
K28.0	Gastrojejunal ulcer: Acute with haemorrhage
K28.1	Gastrojejunal ulcer: Acute with perforation
K28.2	Gastrojejunal ulcer: Acute with both haemorrhage and perforation
K28.3	Gastrojejunal ulcer: Acute without haemorrhage or perforation
K28.4	Gastrojejunal ulcer: Chronic or unspecified with haemorrhage
K28.5	Gastrojejunal ulcer: Chronic or unspecified with perforation
K28.6	Gastrojejunal ulcer: Chronic or unspecified with both haemorrhage and perforation
K28.7	Gastrojejunal ulcer: Chronic without haemorrhage or perforation
K28.9	Gastrojejunal ulcer: Unspecified as acute or chronic, without haemorrhage or perforation
K29.0	Acute haemorrhagic gastritis
K52.9	Non-infective gastroenteritis and colitis, unspecified
L29.0	Pruritus ani
L29.1	Pruritus scroti
L29.2	Pruritus vulvae
L29.3	Anogenital pruritus, unspecified
L29.8	Other pruritus
L29.9	Pruritus, unspecified
L50.0	Allergic urticaria
N17	Acute renal failure
N17.0	Acute renal failure with tubular necrosis
N17.1	Acute renal failure with acute cortical necrosis

N17.2	Acute renal failure with medullary necrosis
N17.8	Other acute renal failure
N17.9	Acute renal failure, unspecified
N18	Chronic kidney disease
N18.0	End-stage renal disease
N18.9	Chronic renal failure, unspecified
N19	Unspecified renal failure
O26.6	Liver disorders in pregnancy, childbirth and the puerperium
O74.6	Other complications of spinal and epidural anaesthesia during labour and delivery
T88.5	Other complications of anaesthesia
Y66	Non administration of surgical and medical care
D50.0	Cod
D61.9	Aplastic Anemia, unspecified
D65	Disseminated intravascular coagulation (defibrination syndrome)
D68.4	Acquired coagulation factor deficiency
D68.9	Coagulation defect, unspecified
D69	Purpura and other haemorrhagic conditions
D69.9	Hemorrhagic condition, unspecified
E86	Volume depletion
E87	Hyperosmolality and hypernatremia
E87.0	Hyperosmolality and hypernatraemia
E87.1	Hypo-osmolality and hyponatraemia
E87.2	Acidosis
E87.3	Alkalosis
E87.4	Mixed disorder of acid-base balance
E87.5	Hyperkalaemia
E87.6	Hypokalaemia
E87.7	Fluid overload
E87.8	Other disorders of electrolyte and fluid balance, not elsewhere classified
F05	Delirium, not induced by alcohol and other psychoactive substances
F15	Mental and behavioural disorders due to use of other stimulants, including caffeine
F16	Mental and behavioural disorders due to use of hallucinogens
F19	Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances
G04.0	Acute disseminated encephalitis
G25.3	Myoclonus
G40.5	Special epileptic syndromes
G71.1	Myotonic disorders
G95.8	Other specified diseases of spinal cord
H11.3	Conjunctival hemorrhage
H21.0	Hyphaema
H31.3	Choroidal hemorrhage and rupture
H35.6	Retinal hemorrhage
H43.1	Vitreous hemorrhage
H92.2	Otorrhagia
126.0	Pulmonary embolism with mention of acute cor pulmonale
I26.9	Pulmonary embolism without mention of acute cor pulmonale
I31.2	Haemopericardium, not elsewhere classified
I44	Atrioventricular and left bundle-branch block
I44.0	Atrioventricular block, first degree
	-

I44.1	A triayantriaylar block googned dograa
I44.1 I44.2	Atrioventricular block, second degree
I44.2 I44.3	Atrioventricular block, complete Other and unspecified atrioventricular block
144.3 I44.4	Left anterior fascicular block
144.4 I44.5	Left posterior fascicular block
144.5 I44.6	-
144.6 I44.7	Other and unspecified fascicular block
144. / I45.8	Left bundle-branch block, unspecified
	Other specified conduction disorders Sudden cardiac death, so described
I46.1	•
I47.2 I60	Ventricular tachycardia
I60 I61	Subarachanoid hemorrhage
I61.0	Intracerebral hemorrhage
	Intracerebral haemorrhage in hemisphere, subcortical
I61.1	Intracerebral haemorrhage in hemisphere, cortical
I61.2	Intracerebral haemorrhage in hemisphere, unspecified
I61.3	Intracerebral haemorrhage in brain stem
I61.4	Intracerebral haemorrhage in cerebellum
I61.5	Intracerebral haemorrhage, intraventricular
I61.6	Intracerebral haemorrhage, multiple localized
I61.8	Other intracerebral haemorrhage
I61.9	Intracerebral haemorrhage, unspecified
I62	Other nontraumatic intracranial hemorrhage
I80	Phlebitis and thrombophlebitis
I80.0	Phlebitis and thrombophlebitis of superficial vessels of lower extremities
I80.1	Phlebitis and thrombophlebitis of femoral vein
180.2	Phlebitis and thrombophlebitis of other deep vessels of lower extremities
I80.3	Phlebitis and thrombophlebitis of lower extremities, unspecified
180.8	Phlebitis and thrombophlebitis of other sites
I80.9	Phlebitis and thrombophlebitis of unspecified site
I95	Hypotension
J38.5	Laryngeal spasm
J45.0	Predominantly allergic asthma
J45.8	Mixed asthma
J81	Pulmonary oedema
K25	Gastric ulcer
K26	Duodenal ulcer
K27	Peptic ulcer, site unspecified
K62.5	Hemorrhage of anus and rectum
K66.1	Hemoperitoneum Toxic liver disease
K71	
K72.0	Acute and subacute hepatic failure
K72.9	Hepatic failure, unspecified
K76.7	Hepatorenal syndrome Hematemesis
K92.0	
K92.1	Melena
K92.2	Gastrointestinal haemorrhage, unspecified
L21	Seborrhoeic dermatitis
L21.0	Seborrhoea capitis
L21.1	Seborrhoeic infantile dermatitis

1.26	Each Parison Assessed to
L26	Exfoliative dermatitis
L28	Lichen simplex chronicus and prurigo
L30	Other dermatitis
L52	Erythema nodosum
L71.0	Perioral dermatitis
M25.0	Hemarthrosis
M31.0	Hypersensitivity angiitis
M62.8	Other specified disorders of muscle
N42.1	Congestion and hemorrhage of prostate
N62	Hypertrophy of breast
N83.6	Hemosalpinx
N83.7	Hematoma of broad ligament
N85.7	Hematometra
N89.7	Hematocolpos
N95.3	States associated with artificial menopause
R00.1	Bradycardia, unspecified
R04.0	Epistaxis
R04.1	Hemorrhage from throat
R04.8	Hemorrhage from other sites in respiratory passage
R04.9	Hemorrhage from respiratory passage, unspecified
R06.0	Dyspnoea
R11	Nausea and vomiting
R17	Unspecified jaundice
R20	Disturbances of skin sensation
R21	Rash and other nonspecific skin eruption
R23	Other skin changes
R23.3	Spontaneous ecchymoses
R31	Unspecified hematuria
R34	Anuria and oliguria
R41.0	Disorientation, unspecified
R42	Dizziness and giddiness
R44.0	Auditory hallucinations
R44.1	Visual hallucinations
R44.2	Other hallucinations
R44.3	Hallucinations, unspecified
R51	Headache
R55	Syncope and collapse
R58	Haemorrhage, not elsewhere classified
R73.9	Hyperglycaemia, unspecified
R74.0	Elevation of levels of transaminase and lactic acid dehydrogenase [LDH]
S06.4	Epidural hemorrhage
T88.2	Shock due to anaesthesia
T88.8	Other specified complications of surgical and medical care, not elsewhere classified
T88.9	Complication of surgical and medical care, unspecified
100.9	Poisoning by and exposure to narcotics and psychodysleptics (hallucinogens) NEC, undetermined
Y12	intent
	Poisoning by and exposure to other and unspecified drugs, medicaments, and biological substances,
Y14	undetermined intent
D68.8	Other specified coagulation defects
G25.0	Essential tremor

I49.0	Ventricular fibrillation and flutter
I85.0	Esophageal varices with bleeding
J46	Status asthmaticus
J80	Adult respiratory distress syndrome
K52.8	Other specified noninfective gastroenteritis and colitis
L20	Atopic dermatitis
L29	Pruritis
N92.1	Excessive and frequent mestruation with irregular cycle
N92.2	Excessive menstruation at puberty
N92.3	Ovulation bleeding
N92.4	Excessive bleeding in the premenopausal period
N92.6	Irregular menstruation, unspecified
N93	Other abnormal uterine and vaginal bleeding
N95.0	Postmenopausal bleeding
R44	Other symptoms and signs involving general sensations and perceptions
S06.5	Traumatic subdural hemorrhage
S06.6	Traumatic subarachanoid hemorrhage
S06.8	Other intracranial injuries
T80.7	Unspecified adverse drug effect
T81	Complications of procedures, not elsewhere classified
Y60.1	Unintentional cut, puncture, perforation or haemorrhage during during infusion or transfusion
Y60.2	Unintentional cut, puncture, perforation or haemorrhage during kidney dialysis or other perfusion
Y60.3	Unintentional cut, puncture, perforation or haemorrhage during injection or immunization
Y62.1	Failure of sterile precautions during infusion or transfusion
Y62.2	Failure of sterile precautions during kidney dialysis or other perfusion
Y62.3	Failure of sterile precautions during injection or immunization
Y64	Contaminated medical or biological substances
Y65.0	Mismatched blood used in transfusion
Z88	Personal history of allergy to drugs, medicaments, and biological substances
A80.0	Acute paralytic poliomyelitis, vaccine-associated
M02.2	Postimmunization arthropathy
T88.0	Infection following immunization
T88.1	Infection complications following immunization

Table A4. Medication Class Distributions Overall and According to Cluster

H03 Thyroid Therapy	H02 Corticosteroids for Systemic Use	G04 Urologicals	D07 Corticosteroids. Dermatological Preparations	D01 Antifungals for Dermatological Use	C10 Lipid Modifying Agents	C09 Agents Acting on the Renin- Angiotensin System	C08 Calcium Channel Blockers	C07 Beta Blocking Agents	C03 Diuretics	C02 Antihypertensives	C01 Cardiac Therapy	B03 Antianemic Preparations	B01 Antithrombotic Agents	A10 Drugs Used in Diabetes	A07 Antidiarrheals, Intestinal Anti- inflammatory/Anti- infective Agents	A06 Drugs for Constipation	A03 Drugs for Functional Gastrointestinal Disorders	A02 Drugs for Acid Related Disorders	Medication Classes	
	roids se	S	roids,	s for Use		m g	ers			/es		c			eals, .nti-		,	Гď	asses	
17,747	13,729	16,102	2,234	3,425	47,317	40,975	29,850	41,797	36,355	2,893	18,874	2,788	56,203	23,337	2,995	31,048	3,869	45,252	Z	Overall (n=188,354)
9.4	7.3	8.6	1.2	1.8	25.1	21.8	15.9	22.2	19.3	1.5	10.0	1.5	29.8	12.4	1.6	16.5	2.1	24.0	% pts	all ,354)
1,066	12	936	74	43	14,154	11,089	4,673	13,487	7,759	405	7,771	98	14,449	2,950	9	937	1	4,010	Z	
4.1	0.1	3.6	0.3	0.2	54.5	42.7	18.0	51.9	29.9	1.6	29.9	0.4	55.6	11.4	·	3.6	•	15.4	% pts cluster	Cluster 1 (n=25,995)
6.0	0.1	5.8	3.3	1.3	29.9	27.1	15.7	32.3	21.3	14.0	41.2	3.5	25.7	12.6	0.3	3.0	(-)	8.9	% class	
2,985	7,283	3,410	683	697	2,992	5,700	6,885	4,648	7,238	507	1,959	578	1,790	4,350	1,240	2,704	813	9,780	Z	
6.3	15.3	7.1	1.4	1.5	6.3	11.9	14.2	9.7	15.2	1.1	4.1	1.2	3.7	9.1	2.6	5.7	1.7	20.5	% pts cluster	Cluster 2 (n=47,737)
16.8	53.1	21.2	30.6	20.4	6.3	13.9	23.1	11.1	19.9	17.5	10.4	20.7	3.1	18.6	41.4	8.7	21.0	21.6	% class	
5,813	2,302	3,388	662	1,471	6,909	6,195	5,503	3,732	4,503	118	1,071	1,055	4,193	2,756	907	7,442	1,498	11,446	Z	
26.3	10.4	15.3	3.0	6.6	31.2	28.0	24.9	16.9	20.3	0.5	4.8	4.8	18.9	12.4	4.1	33.6	6.8	51.7	% pts cluster	Cluster 3 (n=22,147)
32.8	16.8	21.0	29.6	43.0	14.6	15.1	18.4	8.9	12.4	4.1	5.7	37.8	7.5	11.8	30.3	24.0	38.7	25.3	% pts class	
7,187	2,393	6,789	637	1,078	22,308	16,968	11,999	19,209	16,506	1,853	7,928	983	14,342	12,342	650	7,657	1,338	18,266	Z	()
24.9	8.3	23.5	2.2	3.7	77.1	58.7	41.5	66.4	57.1	6.4	27.4	3.4	49.6	42.7	2.3	26.5	4.6	63.2	% pts cluster	Cluster 4 (n=28,924)
40.5	17.4	42.2	28.5	31.5	47.2	41.4	40.2	46.0	45.4	64.1	42.0	35.3	25.5	52.9	21.7	24.7	34.6	40.4	% class	
18	1,708	790	52	54	31	55	47	22	25	0	9	0	418	383	101	934	&	119	Z	
0.1	9.6	4.4	0.3	0.3	0.2	0.3	0.3	0.1	0.1	<u>(-)</u>	0.1	(-)	2.3	2.1	0.6	5.2	(-)	0.7	% pts cluster	Cluster 5 (n=17,867)
1.0	12.4	4.9	2.3	1.6	0.1	0.1	0.2	0.1	0.1	(-)	0.1	(-)	0.7	1.6	3.4	3.0	0.2	0.3	% class	
678	31	789	126	82	923	968	743	699	324	10	136	74	21,051	556	88	11,374	211	1,631	N	(1)
1.5	0.1	1.7	0.3	0.2	2.0	2.1	1.6	1.5	0.7	·	0.3	0.2	46.1	1.2	0.2	24.9	0.5	3.6	% pts cluster	Cluster 6 (n=45,684)
3.8	0.2	4.9	5.6	2.4	2.0	2.4	2.5	1.7	0.9	0.4	0.7	2.7	37.4	2.4	2.9	36.6	5.5	3.6	% class	

S01 Ophthalmologicals	R03 Drugs For Obstructive Airway Diseases	P01 Antiprotozoals	N06 Psychoanaleptics	N05 Psycholeptics	N04 Anti-Parkinson Drugs	N03 Antiepileptics	N02 Analgesics	M05 Drugs for Treatment of Bone Diseases	M04 Antigout Preparations	M01 Anti- inflammatory and Antirheumatic Products	J05 Antivirals for Systemic Use	J01 Antibacterials for Systemic Use
5,894	24,520	4,513	32,555	18,879	3,887	17,386	75,579	7,867	5,057	5,580	1,808	43,107
3.1	13.0	2.4	17.3	10.0	2.1	9.2	40.1	4.2	2.7	3.0	1.0	22.9
286	1,043	40	596	332	65	163	3,471	325	337	65	21	1,256
::	4.0	0.2	2.3	1.3	0.3	0.6	13.4	1.3	1.3	0.3	0.1	4.8
4.9	4.3	0.9	1.8	1.8	1.7	0.9	4.6	4.1	6.7	1.2	1.2	2.9
1,967	9,471	1,336	4,137	3,649	623	2,417	5,668	1,307	819	500	795	10,030
4.1	19.8	2.8	8.7	7.6	1.3	5.1	11.9	2.7	1.7	1.1	1.7	21.0
33.4	38.6	29.6	12.7	19.3	16.0	13.9	7.5	16.6	16.2	9.0	44.0	23.3
1,657	4,787	521	15,534	9,274	2,136	6,640	13,248	3,336	539	1,632	525	5,720
7.5	21.6	2.4	70.1	41.9	9.6	30.0	59.8	15.1	2.4	7.4	2.4	25.8
28.1	19.5	11.5	47.7	49.1	55.0	38.2	17.5	42.4	10.7	29.3	28.9	13.3
1,460	7,156	535	11,4433	4,416	985	5,580	11,021	2,592	3,288	594	351	6,377
5.1	24.7	1.9	39.6	15.3	3.4	19.3	38.1	9.0	11.4	2.1	1.2	22.1
24.8	29.2	11.9	35.2	23.4	25.4	32.1	14.6	33.0	65.0	10.7	19.4	14.8
45	1,742	1,949	24	27	0	12	3,388	7	2	98	106	17,86 7
0.3	9.8	10.9	0.1	0.2	(-)	0.1	19.0	(-)	(-)	0.6	0.6	100
0.8	7.1	43.2	0.1	0.1	(-)	0.1	4.5	0.1	(-)	1.8	5.9	41.5
479	321	132	821	1,181	77	2,574	38,783	300	72	2,691	12	1,857
1.1	0.7	0.3	1.8	2.6	0.2	5.6	84.9	0.7	0.2	5.9	(-)	4.1
8.1	1.3	2.9	2.5	6.3	2.0	14.8	51.3	3.8	1.4	48.2	0.7	4.3

Figure A1. Difference in Prevalence of Medication Classes Dispensed in Each Cluster Compared to Study Population Prevalence





Figure A2. Prevalence of Cluster Membership within each Medication Class



Discharge Table A5. Sensitivity analysis- Association Between Medication Clusters and Risk of ED visits and mortality in 30-days Following

risk	Adjusted OR*
(%)	(95% CI)
Cardiovascular 24.2	0.89 (0.86-0.92)
Respiratory 29.5	1.07 (1.05-1.10)
Complex care needs 25.3	0.80 (0.77-0.83)
Cardiovascular and metabolic 27.1	0.80 (0.77-0.82)
Infection 33.2	1.33 (1.28-1.38)
Surgical 24.0	

^{*}Reference is all other clusters (e.g., cardiovascular vs not)

Table A6. Association between medication class and ED visits/mortality and ADEs in 30-days following discharge

		Adv	erse drug	Adverse drug events in 30-days	SVE			ED	visits/mo	ED visits/mortality in 30-days	SVS	
	0	Overall	Con	Continued	ŧ	New	0	Overall	Con	Continued		New
	Crude	Adjusted	Crude	Adjusted	Crude	Adjusted	Crude	Adjusted	Crude	Adjusted	Crude	Adjusted
Medication Class	risk	08*	risk	08*	risk (0/)	OR*	risk	08*	risk	OR*	risk	OR*
A02 Drugs for Acid	8.1	1.02	7.9	0.96	8.5	1.17	28.2	1.00	28.2	0.98	30.7	1.08
A03 Drugs for		(0:27 1:07)		(0.71 1.01)		(1.10 1.20)		(0.27 1.02)		(0.20 1.01)		(1.0 1.10)
Functional	>	1.12	o o	1.06	100	1.27) n 2	1.14	7	1.08	; `	1.31
Gastrointestinal Disorders	9.0	(1.00-1.25)	0.0	(0.92-1.23)	10.9	(1.07-1.51)	33.4	(1.06-1.27)	32.7	(0.98-1.18)	45.0	(1.16-1.47)
A06 Drugs for	6.7	1.01	7.6	0.91	6.3	1.06	27.3	1.00	28.5	0.92	28.1	1.04
A07 Antidiarrheals		(0.20 1.00)		(0.01 0.00)		(0.22 1.12)		(0.27 1.02)		(0.07 0.70)		(1:01 1:00)
Intestinal Anti-	100	1.21	100	1.27	100	1.17	37 &	1.01	21 /	0.96	26.1	1.05
inflammatory/Anti-	10.0	(1.07-1.37)	10.0	(1.05-1.54)	10.0	(1.00-1.38)	32.0	(0.92-1.10)	1.10	(0.94-1.09)	70.4	(0.94-1.17)
infective Agents												
A10 Drugs Used in Diabetes	7.9	0.92 (0.8798)	7.4	0.88 $(0.92-0.94)$	9.5	1.10 (1.00-1.21)	26.4	0.84 $(0.81-0.87)$	26.0	0.82 (0.80-0.87)	29.8	0.97 $(0.91-1.03)$
B01 Antithrombotic Agents	6.5	1.04 $(0.99-1.09)$	8.1	1.00 $(0.94-1.06)$	5.7	$ \begin{array}{c c} 1.07 \\ (1.01-1.13) \end{array} $	24.0	1.02 $(0.99-1.05)$	26.9	0.95 $(0.91-0.98)$	23.3	1.07 $(1.03-1.10)$
B03 Antianemic Preparations	8.7	1.08 $(0.94-1.23)$	8.6	1.05 (0.90-1.24)	9.0	1.17 (0.92-1.50)	27.7	0.95 $(0.87-1.04)$	27.6	0.94 $(0.84-1.05)$	30.1	1.02 $(0.87-1.20)$
C01 Cardiac Therapy	9.2	$ 1.07 \\ (1.00-1.14) $	8.7	0.94 $(0.87-1.02)$	9.5	1.16 (1.07-1.25)	29.3	$ \begin{array}{c c} 1.06 \\ (1.02 - 1.10) \end{array} $	28.9	0.96 $(0.91-1.02)$	29.6	1.11 (1.06-1.16)
C02 Antihypertensives	12.7	$1.26 \\ (1.12-1.42)$	10.9	$ \begin{array}{c} 1.08 \\ (0.92 - 1.27) \end{array} $	15.2	1.51 (1.28-1.78)	34.1	$ \begin{array}{c c} 1.11 \\ (1.02-1.21) \end{array} $	32.4	0.95 $(0.84-1.06)$	39.8	1.35 (1.19-1.52)
C03 Diuretics	9.4	1.11 (1.06-1.17)	9.2	$ \begin{array}{c} 1.05 \\ (0.99-1.11) \end{array} $	9.7	1.20 (1.12-1.29)	28.4	$0.98 \\ (0.95-1.01)$	28.7	0.99 (0.96-1.03)	29.1	1.01 (0.97-1.06)
C07 Beta Blocking Agents	8.5	$ \begin{array}{c} 1.08 \\ (1.03 - 1.13) \end{array} $	8.4	1.03 $(0.98-1.09)$	8.7	$ \begin{array}{c c} 1.15 \\ (1.07-1.23) \end{array} $	27.6	$ \begin{array}{c c} 1.02 \\ (1.00-1.05) \end{array} $	27.2	0.95 $(0.92-0.98)$	29.2	1.14 $(1.09-1.19)$
C08 Calcium Channel	7.8	1.01	7.7	0.99	8.3	1.10	25.6	0.92	25.6	0.90	27.5	1.01
				\\\\		\		(/		(/		

dRxiv pro which)	eprint c was no	ioi: http t certifi	ed by p	org/10. eer rev	1101/2022 view) is the	author	/funder, wl	; this ve	ersion p granțe	d medF	August Rxiv a li	30, 202 cense t	22. The co o display t	pyright he prep	nolder orint in	for this pre perpetuity.
N06 Psychoanaleptics	N05 Psycholeptics	N04 Anti-Parkinson Drugs	N03 Antiepileptics	N02 Analgesics	EM05 Drugs for Treatment of Bone Diseases	©M04 Antigout ePreparations	eM01 Anti-inflammatory Sand Antirheumatic Products	all J05 Antivirals for gSystemic Use	Systemic Use	EH03 Thyroid Therapy	ESystemic Use	eG04 Urologicals	D07 Corticosteroids, Dermatological Preparations	D01 Antifungals for Dermatological Use	C10 Lipid Modifying Agents	C09 Agents Acting on the Renin-Angiotensin System
7.3	7.5	6.7	7.8	5.6	6.6	10.4	4.3	6.4	6.8	7.8	8.9	7.6	6.6	6.6	7.2	6.9
0.90 (0.85-0.95)	0.97 (0.91-1.03)	0.91 (0.80-1.04)	1.09 (1.02-1.16)	0.90 (0.86-0.94)	0.92 (0.83-1.01)	1.12 (1.02-1.24)	0.84 (0.74-0.96)	0.80 (0.66-0.97)	0.95 (0.91-1.00)	0.96 (0.90-1.02)	1.14 (1.07-1.23)	0.97 $(0.91-1.04)$	0.85 (0.72-1.01)	0.80 (0.70-0.92)	0.90 $(0.85-0.94)$	0.91 (0.86-0.95)
7.3	7.4	7.0	7.9	6.7	7.0	10.3	4.3	6.1	7.0	7.8	8.9	7.6	6.8	6.2	7.4	6.8
0.93 (0.88-0.99)	0.98 (0.91-1.06)	0.95 (0.83-1.09)	1.05 (0.97-1.13)	0.88 (0.83-0.93)	0.97 (0.88-1.07)	1.14 (1.03-1.27)	0.76 (0.62-0.93)	0.70 (0.48-1.02)	0.93 (0.84-1.02)	0.98 (0.92-1.05)	1.07 (0.98-1.17)	0.97 (0.90-1.04)	0.87 (0.70-1.06)	0.72 (0.58-0.90)	0.96 (0.91-1.01)	0.92 (0.87-0.97)
7.1	7.7	4.4	7.6	5.1	4.2	12.0	4.3	6.5	6.7	7.3	8.9	7.6	6.3	6.9	6.6	7.0
0.92 (0.83-1.02)	0.98 (0.89-1.08)	0.62 (0.39-1.00)	1.25 (1.12-1.40)	0.95 (0.90-1.00)	0.70 (0.53-0.93)	1.39 (1.05-1.83)	0.90 (0.76-1.08)	0.88 (0.70-1.02)	0.97 (0.92-1.02)	1.04 (0.82-1.33)	1.23 (1.12-1.35)	1.06 (0.93-1.19)	0.84 (0.62-1.14)	0.85 (0.71-1.01)	0.89 (0.82-0.97)	0.93 (0.86-1.01)
25.3	28.6	24.5	27.5	25.7	21.2	31.6	21.3	26.4	30.1	25.8	35.2	30.4	22.8	22.8	24.4	23.7
0.85 (0.82-0.88)	1.01 (0.97-1.05)	0.90 (0.83-0.97)	1.01 (0.97-1.05)	1.03 (1.00-1.06)	0.83 (0.79-0.88)	1.04 (0.98-1.11)	0.94 (0.88-1.01)	0.80 (0.71-0.90)	1.05 (1.02-1.08)	0.93 (0.89-0.97)	1.17 (1.12-1.22)	1.11 (1.06-1.15)	0.77 (0.70-0.85)	0.82 (0.75-0.89)	0.84 (0.82-0.87)	0.88 (0.85-0.91)
26.1	27.4	25.5	28.4	29.4	22.4	30.3	21.9	30.1	33.9	25.9	35.8	27.6	22.6	22.8	24.9	23.9
0.88 (0.85-0.92)	0.91 (0.87-0.95)	0.95 (0.88-1.03)	0.97 (0.93-1.01)	0.94 (0.91-0.97)	0.88 (0.82-0.94)	1.02 (0.95-1.09)	0.85 (0.77-0.94)	0.90 (0.73-1.11)	1.06 (1.01-1.11)	0.95 (0.91-1.00)	1.05 (0.99-1.11)	0.94 (0.90-1.00)	0.75 (0.66-0.85)	0.77 (0.68-0.88)	0.88 (0.85-0.91)	0.89 (0.86-0.92)
26.4	34.6	21.0	30.6	25.9	16.3	45.9	24.2	27.3	29.8	26.9	36.7	40.1	23.3	25.6	23.9	24.3
0.89 (0.84-0.95)	1.23 (1.16-1.31)	0.71 (0.55-0.92)	1.16 (1.09-1.25)	1.07 (1.04-1.10)	0.67 (0.57- 0.79)	1.63 (1.35-1.96)	1.10 (0.92-1.10)	0.78 (0.68-0.89)	1.07 (1.04-1.10)	0.89 (0.77-1.03)	1.27 (1.20-1.35)	1.66 (1.56-1.78)	0.83 (0.70-0.99)	0.82 (0.74-0.92)	0.90 (0.86-0.95)	0.89 (0.86-0.94)

S01 Ophthalmologicals Obstructive Airway R03 Drugs For P01 Antiprotozoals 5.7 7.7 8.3 (1.09-1.37)(0.64-0.81)(0.86-0.97)0.92 1.22 5.9 9.6 7.4 0.76 (0.67-0.86) 0.86 (0.80-0.93) (1.00-1.63)1.28 4.9 8.0 8.0 1.00 (0.93-1.08) (0.45-0.76)(1.07-1.37)1.21 27.5 31.6 22.8 0.88 (0.85-0.91) (0.72 - 0.82)(1.07-1.23)1.15 20.6 27.5 33.6 0.86 (0.83-0.90) (0.64-0.74)(0.97-1.33)1.14 28.1 31.6 0.93 (0.89 -0.97) (0.93-1.20)(1.10-1.28)1.06 1.18